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ABSTRACT

D’Aquila, Theresa M. Ph.D., Purdue University, August 2016. Intestinal Cytoplasmic
Lipid Droplets, Associated Proteins, and the Regulation of Dietary Fat Absorption. Major
Professor: Kimberly Buhman.

Dietary fat provides essential nutrients, contributes to energy balance, and
regulates blood lipid concentrations. These functions are important to health, but can also
become dysregulated and contribute to diseases such as obesity, diabetes, and
cardiovascular disease. The small intestine absorbs dietary fat through an efficient multi
step process of digestion, uptake, metabolism, and secretion or storage. When dietary fat
is taken up by the absorptive cells of the small intestine, enterocytes, it can be secreted
into circulation where it contributes to blood lipid levels or temporarily stored in
cytoplasmic lipid droplets (CLDs). The objective of this dissertation is to investigate the
presence and metabolism of CLDs in the intestine.
Dietary fat absorption by the small intestine is a multi-step process that regulates
the uptake and delivery of essential nutrients and energy. One step of this process is the
temporary storage of dietary fat in cytoplasmic lipid droplets (CLDs). The storage and
mobilization of dietary fat is thought to be regulated by proteins that associate with the
CLD; however, mechanistic details of this process are currently unknown. In this study
we analyzed the proteome of CLDs isolated from enterocytes harvested from the small
intestine of mice following a dietary fat challenge. In this analysis we identified 181

xvi
proteins associated with the CLD fraction, of which 37 are associated with known lipid
related metabolic pathways. We confirmed the localization of several of these proteins on
or around the CLD through confocal and electron microscopy, including perilipin 3,
apolipoprotein A-IV, and acyl-CoA synthetase long-chain family member 5. The
identification of the enterocyte CLD proteome provides new insight into potential
regulators of CLD metabolism and the process of dietary fat absorption.
We also investigated the effect of diet induced obesity on CLD morphology and
associated proteins. It is currently unclear what effect diet induced obesity (DIO) has on
the balance between dietary fat storage and secretion. Specifically, there is limited
knowledge of how DIO affects the level and diversity of proteins that associate with
CLDs and regulate CLD dynamics. In the current study, we characterize CLDs from lean
and DIO mice through histological and proteomic analyses. We demonstrate that DIO
mice have larger intestinal CLDs compared to lean mice in response to dietary fat.
Additionally we identified 375 proteins associated with CLDs in lean and DIO mice. We
identify a subgroup of lipid related proteins which are either increased or unique to the
DIO CLD proteome. These proteins are involved in steroid synthesis pathways, TAG
synthesis, and lipolysis. This analysis expands upon our knowledge of the effect of DIO
obesity on the process of dietary fat absorption in the small intestine.
Lastly, we investigated the role of one of the newly identified CLD associated
proteins on dietary fat absorption. Little is known of the role of Acsl5 in the metabolism
of dietary fat in enterocytes. To understand the role of Acsl5 in dietary fat absorption, we
challenged WT and Acsl5-deficient mice with acute and chronic dietary fat challenges.
Despite no evidence of quantitative fat malabsorption in the absence of Acls5, we found

xvii
significantly reduced TAG storage and secretion by enterocytes compared to WT mice.
Interestingly, Acsl5-deficient consumed more food, but did not gain more weight
compared to WT mice during two weeks of HFD feeding. Furthermore, we found that
Acsl5 localizes to the nucleus after an acute dietary fat challenge. Together this data
suggests that although Acsl5 is not essential for quantitative dietary fat absorption, it
plays a role in intestinal metabolism of dietary fat.
The results presented in this dissertation provide new knowledge of regulators of
CLD metabolism. The long term objectives of these studies are to identify mechanistic
details of the process of intestinal dietary fat absorption. Understanding the process of
dietary fat absorption will provide new treatments for the prevention of diseases
associated with dyslipidemia.
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CHAPTER 1. INTRODUCTION

1.1

1.1.1

Dietary fat, health, and disease

Dietary fat structure and composition

Dietary fat represents a diverse group of chemical compounds with different
structures, functions, health benefits, and risk for disease. Dietary fat is a broad
classification for lipid compounds which are consumed[1]. Dietary fat can be found from
both animal and plant sources and is a significant source of energy. In the western diet,
dietary fat accounts for approximately 35% of calories consumed. The predominant form
of dietary fat consumed is the form of long chain triacylglycerol (TAG), which is
composed of 3 fatty acids esterified to a glycerol backbone. Dietary fat also contains
smaller amounts of cholesteryl esters (CE) and phospholipids (PL). Fatty acids are
present within TAG, CE, or PL and consist of a chain of carbons of various chain lengths
and degree of saturation. Fatty acid species include saturated fatty acids,
monounsaturated fatty acids, polyunsaturated fatty acids (including omega 6 and 3 fatty
acids) and trans-fatty acids.

Portions of this section have been previously published in:
T. D'Aquila, Y.H. Hung, A. Carreiro, K.K. Buhman, Recent discoveries on absorption of
dietary fat: Presence, synthesis, and metabolism of cytoplasmic lipid droplets within
enterocytes, Biochimica et biophysica acta, 1861 (2016) 730-747.
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1.1.2

Dietary fat, fat soluble vitamins, and essential fatty acids

Dietary fat plays a critical role in health by promoting the absorption of essential
nutrients of fat soluble vitamins and essential fatty acids[2]. Vitamins A (in the form of
retinol esters), vitamin D, vitamin E, and vitamin K, are fat soluble vitamins whose
absorption is dependent on the presence of fat in the diet. These vitamins enter the
circulation as components of chylomicrons [2] [3]. Malabsorption of these vitamins may
lead to deficiency and ultimately xerophthalmia, rickets, neuromuscular disorders,
hemorrhaging. Essential fatty acids are also absorbed by the intestine and secreted into
circulation [4]. Essential fatty acid deficiency, while rare, can result in neurological and
cognitive development problems. The small intestine plays an essential role in the
absorption of fat soluble vitamins, essential fatty acids, and promotion of health.

1.1.3

Dietary fat and risk for disease

Dietary fat plays a critical role in the etiology of cardiovascular disease [5]. The
association of diet composition and risk for coronary heart disease has been extensively
studied for the last 50 years. Despite intense investigation, the link between dietary fat
and coronary heart disease is a contested subject. In 1977, public health officials
recommended to limit intake of dietary fat to less than 30% of daily calories in an effort
to reduce the risk for coronary artery disease[6]. To assess the impact of these
recommendations, The Women's Health Initiative Randomized Controlled Dietary
Modification Trial, tested low fat (20% kcal from fat)/high carbohydrate intervention diet
against a usual diet (>32% kcal from fat) group. This study demonstrated no effect of
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reducing dietary fat on risk for coronary artery disease and cardiovascular disease [7].
This lack luster result shifted the attention from total dietary fat to dietary fatty acid
composition.
Diets high in saturated fat have been implicated in an increased risk for coronary
artery disease. Dietary intervention trials which reduced saturated fat or replaced
saturated fat with other fatty acid types reduced cardiomorbidity and cardiovascular
events, but no had effect on cardiovascular mortality [8]. Based on numerous intervention
trials and meta-analyses, the National Heart Foundation of Australia recommended
reducing saturated and trans-fat intake and increasing omega 3, omega 6, and
monounsaturated fatty acid intake, to reduce the risk of cardiovascular disease [9].
The United States has recently changed dietary guidelines to help Americans eat a
healthier diet. The 2015 dietary guidelines suggest limiting the intake of calories from
saturated fat to less than 10% of total calories. Additionally, the dietary guideline
advisory committee suggests replacing saturated fat with polyunsaturated fat to reduce
the risk for coronary artery disease [10]. More specifically, current guidelines suggest
reducing trans fats and saturated fats to 1 and 7% respectively and replacing these fats
with polyunsaturated and monounsaturated fatty acids [11]. Understanding the molecular
mechanisms by which the small intestine absorbs dietary fat is critical for the prevention
and treatment of diseases associated with dyslipidemia.

4
1.2

Intestinal metabolism of dietary fat

1.2.1

Digestion and uptake of dietary fat

The small intestine absorbs dietary fat through an efficient multi step process of
digestion, uptake, metabolism, and secretion or storage. Dietary fat absorption is an
extremely efficient process (greater than 98%) even when large amounts of dietary fat are
consumed [12]. Disruption of the process of dietary fat digestion, uptake, metabolism,
and secretion results in fat malabsorption as indicated by steatorrhea or presence of fat in
the feces.
Dietary fats are digested and emulsified in the lumen of the small intestine and
ultimately taken up by enterocytes through the apical brush border membrane. Crude
emulsion of dietary fat enters the small intestine from the stomach and is combined with
bile acids from the gall bladder/liver and pancreatic juices. In the lumen of the small
intestine, dietary fat is emulsified into mixed micelles with bile acids and phospholipids
and undergo hydrolysis by pancreatic lipase [13]. The digestion of dietary TAG results in
the production of free fatty acids (FFA) and sn-2 monoacylglycerol (MAG) [14] that are
emulsified with bile generating mixed micelles and presented to the brush border
membrane of enterocytes.

5
1.2.2

Fatty acid uptake and metabolism

FFA and MAG are taken up by enterocytes however the mechanisms through
which this occurs is not completely clear. MAG passively diffuses across the plasma
membrane of enterocytes [15]. FFA on the other hand may be taken up by the enterocytes
by passive diffusion or by protein mediated uptake [16]. FFA may diffuse passively
across the plasma membrane via a flip flop mechanism. Since long chain fatty acid
(LCFA) uptake by diffusion is a saturable process [17], a protein dependent mechanism
has been proposed to promote cellular uptake of FFA. FFA may be facilitated across the
plasma membrane by CD36, by enterocytes in the proximal section of the small intestine.
Isolated enterocytes from the proximal section of CD36 deficient mice have decreased
rate (50%) of fatty acid uptake [18]. In particular, CD36 has a high affinity and promotes
absorption of very long chain fatty acids [19]. FFA may be facilitated across the plasma
membrane by fatty acid transport protein 4 (FATP4). FATP4 is present on the apical side
of the enterocyte and when overexpressed, increases the uptake of LCFA [20].
Interestingly, both CD36 and FATP4 deficient mice have no fat malabsorption. It has
been suggested that CD36 and FATP4 may play important however non-essential roles in
regulating dietary fat absorption. Although the mechanism through which fatty acids are
taken up is unclear, the intestine is capable of responding to high lipid load as
demonstrated by low fecal lipid content in healthy humans.
FFA may be metabolically trapped in enterocytes via fatty acid binding proteins
and directed toward specific metabolic fates. The upper region of the small intestine
expresses two fatty acid binding proteins (FABP), FABP1 or liver FABP and FABP2 or
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intestinal FABP. Both FABP1 and FABP2 are highly expressed in the small intestine and
have a high affinity for LCFA [21]. It is hypothesized that FABP1 and FABP2 bind to
FFA in enterocytes and limit the toxic effects of FFA [22]. FABP1 has high binding
affinity for fatty acids but also other lipid species such as lysophospholipids, MAG, fatty
acyl-coA, and prostaglandins [23]. FABP1 deficient mice have increased deposition of
lumenally derived MAG into PL, MAG, and diacylglycerol (DAG) and with a decreased
deposition in TAG. This data indicates FABP1 directs dietary MAG toward TAG
synthesis. FABP1 deficient mice have a decrease deposition of lumenally derived fatty
acids into mucosal oxidation indicating FABP1 directs fatty acids toward oxidation [24].
FABP2 on the other hand has a high binding affinity for fatty acids but has not been
shown to have non fatty acid ligands. FABP2 deficient mice have increased deposition of
lumenally derived fatty acids into PL and decreased into TAG indicating FABP2 directs
fatty acids into TAG synthesis and away from PL synthesis. Interestingly, both FABP1
and FABP2 deficient mice do not have fat malabsorption as indicated by steatorrhea on
chow or high fat diets. While the roles of these two proteins in the intestine is not
completely clear, FABP1 and FABP2 may play a role in fatty acids transport and
targeting of fatty acids towards different metabolic fates [25].
FFA may be metabolically trapped in enterocytes by conversion to fatty acyl-CoA
and directed toward specific metabolic fates. The thioesterification of LCFA to a long
chain fatty acyl-CoA is catalyzed by long chain fatty acyl-CoA synthetases (ACSLs) and
is an obligatory step in the cellular lipid metabolism. There are at least 25 different acylCoA synthetases with different tissue distribution patterns [26]. The primary ACSLs
found in the intestine are Fatp4 and Acsl5. Acyl-CoA synthetases can promote cellular
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fatty acid uptake via vectorial acylation [27]. Vectorial acylation has not been
investigated in the small intestine, however FATP4 inhibition in isolated enterocytes by
antisense oligonucleotides reduces the uptake of LCFA [20]. The role of Acsl5 in fatty
acid uptake in enterocytes is unknown. In addition to driving fatty acid uptake, ACSLs
have been proposed to partition fatty acids toward specific metabolic fates [28]. ACSL
partitioning of fatty acids has been characterized in other cell types but has not been fully
investigated in enterocytes. Acsl5 directs fatty acyl-coA toward TAG synthesis in a cell
model of hepatocytes [29]. The role of Acsl5 in intestinal dietary fat absorption has not
been thoroughly investigated. Initial report of Acsl5 deletion in mice shows a 60%
decrease in jejunal ACSL activity but no difference in TAG secretion in response to an
acute dietary fat challenge [30]. Intestinal deletion of FATP4 does not affect TAG
secretion or fecal lipid content in response to an acute dietary fat challenge, however
iFATP4 deficient mice have increased fecal lipid TAG content when placed on a Western
diet when compared to wild type mice [31]. The investigators report no changes in
expression of other FATPs in iFATP4 deficient mice, however Acsl5 expression was not
measured and potentially compensates for loss of iFATP4. These results indicate highly
expressed ACSLs in the intestine are dispensable for dietary fat absorption.

1.2.3

Fatty acid re-esterification

Fatty acids are re-esterified generating a TAG molecule through the glycerol-3phosphate (G3P) and acyl-coA: monoacylglycerol acyltransferase (MGAT) pathways.
The first step in the G3P pathway is the acylation of G3P, which is catalyzed by glycerol-
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3-phosphate acyltransferase (GPAT) enzymes and yields lysophosphatidic acid [32]. In
the small intestine, two isoforms of GPAT are expressed: GPAT3 (high expression,
jejunum) and GPAT4 (moderate expression) [32-34]. Gpat3-deficient mice have
decreased TAG secretion and increased TAG storage in enterocytes following a dietary
fat challenge [33]. The lysophophatidic acid formed during this first reaction is then
acylated by acylglycerolphosphate acyltransferase (AGPAT) enzymes, also known as
lysophosphatidic acid acyltransferases, to form phosphatidic acid. In the small intestine,
AGPAT2, AGPAT4 or AGPAT8 may contribute to the formation of phosphatidic acid.
Lipin enzymes, or phosphatidic acid phosphatases (PAPs), then remove the phosphate
group to form DAG. Lipin-3 mRNA is present in the small intestine of mice and humans
[35]. The presence of players in the G3P pathway and results found in Gpat3-deficient
mice highlight that this pathway may play a more important role in intestinal TAG
metabolism than previously recognized.
Alternatively, free fatty acids may be re-esterified by the MGAT pathway. MGAT
activity accounts for 70-80% of TAG generated for secretion [36]. Multiple MGAT
enzymes have been identified and are differentially expressed in tissues and species. The
first step of the MGAT pathway for TAG synthesis is the acylation of MAG by fatty
acyl-CoA to produce DAG, which is catalyzed by MGAT activity (reviewed in [37]).
MGAT activity is highest in the proximal small intestine and progressively decreases in
distal regions [38]. Three MGAT isoforms have been identified, but only MGAT2 and
MGAT3 are present in the small intestine [39]. MGAT2 is abundant in the intestine of
both mice and humans, with both mRNA and protein levels reflecting MGAT activity
along the length of the small intestine [38]. MGAT3, on the other hand, is expressed in
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humans, but not mice, and is highest in the ileum [40]. The role of MGAT2 in dietary fat
absorption has been investigated in mouse models. Mgat2 protein and mRNA levels
increase in response to a high fat diet, suggesting this enzyme contributes to the increase
in MGAT activity that occurs during dietary fat absorption [38]. Two different Mogat2deficient mouse models were generated to understand the function of Mgat2 in intestinal
TAG synthesis and dietary fat absorption [41, 42]. Although these mice still synthesize
TAG in enterocytes and secrete CM-sized lipoproteins, they exhibit a reduced
postprandial triglyceridemic response and a decreased TAG secretion rate in response to
an oral fat load compared to wild-type mice [41, 42]. In addition, they remain efficient at
absorbing dietary fat when fed a high fat diet. These results suggest that although other
enzymes must be present to catalyze this activity, the fate of TAG synthesized in
enterocytes may be different in Mogat2-deficient mice than wild-type mice. In fact, while
less TAG is secreted in the Mogat2-deficient mouse models, more TAG is found in CLDs
of jejunal enterocytes in Mogat2-deficient mice fed a high fat diet than in wild-type mice
[41]. Similar effects have been observed in intestine-specific Mogat2-deficient mice [43]
and in mice treated with an MGAT2 inhibitor [44]. In addition, restoring Mogat2
expression specifically in the intestine of Mogat2-deficient mice normalized the TAG
absorption rate [45]. Together these results suggest that MGAT2 is not critical for
absorption, but important for balancing intestinal TAG storage and secretion. Whether
DAG is generated via G3P or MGAT pathway, the final step in TAG synthesis is
catalyzed by Acyl- CoA: diacylglycerol acyltransferase (DGAT).
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1.2.4

Triacylglycerol synthesis

Acyl Co-A: diacylglycerol acyltransferase (DGAT) catalyzes the final step in
TAG synthesis. Two proteins with DGAT activity have been identified and investigated
in intestinal lipid metabolism. DGAT enzymes catalyze the acylation of DAG, resulting
in the formation of TAG [37, 39]. This reaction is the final, committed step of TAG
synthesis, and is the point at which the MGAT and G3P pathways converge. Evidence of
DGAT activity on both the luminal (latent activity) and cytosolic (overt activity) sides of
the ER in rat liver microsomes suggests that distinct pools of TAG destined for storage
and secretion may be present in lipoprotein-producing cells [46]. Total DGAT activity is
highest in the proximal intestine and decreases distally along the length of the intestine
[47]. The two known DGAT enzymes, DGAT1 and DGAT2, are both integral ER
membrane proteins and are both present in the small intestine. DGAT2 has also been
shown to localize to CLDs and associate with mitochondria in other cell types [48, 49].
Although both of these enzymes catalyze the same reaction, they are members of two
different gene families, and differ from one another in terms of structure, expression
pattern, and biochemical properties. This suggests that DGAT1 and DGAT2 may play
unique roles in synthesizing TAG for storage versus secretion in enterocytes.

1.2.5

Chylomicron synthesis and secretion

TAG can be packaged onto chylomicrons (CM) for secretion from enterocytes.
CMs are the major TAG rich lipoprotein produced by enterocytes in response to a meal
containing dietary fat (reviewed in [2, 50]). CMs are made by a two-step pathway within

11
the ER and are then secreted via pre-CM transport vesicles (PCTVs) through the Golgi
and secretory pathway on the basolateral side of the enterocyte to lymph [51]. First,
TAGs and CEs are synthesized by enzymes that localize to the ER membrane. These
neutral lipids are packaged onto apolipoprotein (APO) B48 with the help of microsomal
triglyceride transfer protein (MTP or Mttp) [52]. APOB48 serves as a lipid acceptor and
structural protein of CMs. MTP serves as a lipid transfer protein and chaperone for
maintaining APOB48 structure. The neutral lipids, TAGs and CE, are surrounded by a PL
monolayer containing free cholesterol and proteins. This initial structure is referred to as
the primordial CM [53]. The second step in the synthesis of pre-CMs is the expansion of
the CM core by TAG [54]. The mechanisms underlying the addition of TAG is unclear
but it is known that MTP is required, and apoB-free ER lumenal lipid droplets (LLDs) are
the most likely source of TAG for core expansion [55, 56] . One possible mechanism for
this expansion is the fusion of LLDs with primordial CMs. Alternatively, it has been
suggested that hydrolysis and re-esterification of LLDs may provide lipids for the second
step of core expansion during CM assembly [55].
Pre-CMs exit the ER and are transported to the Golgi for further processing.
These particles are transported within PCTVs containing coat protein complex II (COPII).
COPII is made up of five core proteins: secretion associated, Ras related 1B (Sar1B)
GTPase, Sec23, Sec24, Sec13, and Sec31 [56, 57]. The budding of PCTVs from the
surface of the ER is mediated by liver fatty acid binding protein [58, 59] and protein
kinase C isoform zeta [60]. PCTVs are larger than protein transport vesicles (250 nm
versus 55–70 nm, respectively) and also contain the unique vesicle-associated membrane
protein 7 [61]. After budding, the PCTV fuses with the cis-Golgi [62]. Within the Golgi,
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pre-CMs are further modified by addition of APOAI [63] and glycosylation of APOB48
[64]. Mature CMs are then destined for secretion where they are released from the
basolateral side of the enterocyte by exocytosis to the lamina propria as imaged by
transmission electron microscopy [65, 66]. The contractile movement of lacteals mediates
the process of CM drainage to mesenteric lymphatic vessels [67]. CMs are then
transported via the thoracic duct that empties into circulation at the left subclavian vein.
In addition to the nonexchangeable APOB48, several exchangeable apolipoproteins can
be found on the surface of CMs, including APOAI, APOAII, APOAIV, APOC and
APOE [68].
The importance of the role in dietary fat absorption in health is highlighted by
human congenital disorders where proteins chylomicron synthesis and secretion are
defective or deficient [69]. Deficiencies in ApoB, Mttp, and Sar1b result in
hypobetalipoproteinemia, abetalipoproteinemia, and chylomicron retention disease
respectively. These diseases are characterized by fat malabsorption presenting as
steatorrhea, low blood lipid (TAG and CHOL) levels, deficiencies in fat soluble vitamins
and essential fatty acids and ultimately failure to thrive.

1.2.6

Cytoplasmic lipid droplets and triacylglycerol storage

Alternatively to secretion in CM, dietary TAG can be stored in CLDs within
enterocytes. The partitioning of TAG into CM synthesis has been well characterized and
less is known regarding the synthesis and catabolism of CLDs in enterocytes. The
balance between TAG storage and secretion regulates the appearance of TAG in the
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blood. The molecular mechanisms of CLD metabolism in enterocytes are relatively
unknown. Identification of mediators of intestinal CLD metabolism has the potential to
significantly impact the dietary fat absorption and ultimately health and disease.

1.3

1.3.1

Cytoplasmic lipid droplet metabolism

General knowledge of CLD metabolism

1.3.1.1 Physiological conditions promoting CLDs
Cytoplasmic lipid droplets are the main site of lipid storage in eukaryotic cells.
CLDs are efficient stores of excess energy and are generated when nutrients are present
in excess. Almost every cell type is capable of generating CLDs, however the size,
number, composition, and metabolism of CLDs varies based on cell type and
physiological conditions. While CLD characteristics differ, there are some common
features. This section will highlight general characteristics of CLD biology and
metabolism and the following sections will focus on CLDs specifically in the small
intestine.

1.3.1.2 CLD composition
CLDs are composed of a neutral lipid core, surrounded by a phospholipid
monolayer and a coat of associated proteins. Additionally, CLDs may be physically
connected or closely associated with other organelles which contribute to the metabolism
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and function of CLDs. The composition of CLD components vary based on cell type and
physiological condition. For example, CLDs in adipocytes are long term energy stores
while CLDs in hepatocytes and enterocytes are more transient stores for excess fatty
acids. Additionally, the presence, composition, and metabolism of CLDs may affect cell,
tissue, and organism, physiology and function.

1.3.1.2.1 Neutral and phospholipid composition
CLDs are composed of a neutral lipid core with a phospholipid monolayer coat.
The neutral lipid core is predominantly TAG and sterol esters however additional
hydrophobic compounds have been detected in isolated CLDs albeit at much lower levels.
These lipid species include retinyl esters, wax esters, and ether lipids [70, 71]. The
surface of the CLD is comprised of phospholipids, mainly phsophstidylcholine,
phosphatidylethanolamine, and phosphatidynlinositol [70]. This amphipathic interface
allows for the interaction with proteins and other organelles [72].

1.3.1.2.2 General CLD associated proteins
Various proteins associate with the CLD and regulate CLD metabolism. Perilipin
(Plin) was the first protein identified associated with the CLD in 1991 [73]. Since the
initial discovery of Plin, other members of the perilipin family have been identified
across species with similar sequence and ability to bind to CLDs [74]. The members of
the perilipin family include, Plin1 (Perilipin), Plin2 (Adipocyte differentiation related
protein or ADRP), Plin3 (47 kDa mannose 6-phosphate receptor-binding protein or TIP-
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47), Plin4 (Adipocyte protein S3-12, or S3-12), and Plin5 (Lipid droplet-associated
protein PAT-1 or OxPAT). It is still unclear what role the different Plin family members
play in regulating CLD metabolism. While members of the Plin family are often
characterized as regulators of CLD catabolism, new research suggest a potential role in
glucose homeostasis [75, 76]. A large number of studies have been performed to identify
additional proteins associated with CLDs from a variety of cell types under various
physiological conditions. Fueled by technological advances and association of CLDs with
various metabolic disorders, the field of CLD biology has advance dramatically in the last
10 years.
A current gap in the field revolves around the targeting proteins to CLDs. Proteins
may embed directly into the CLD by a hydrophobic hairpin motif or associate with the
surface of the CLD by amphipathic helices or hydrophobic domains [77]. Additionally
the ability of a protein to bind to CLDs may change during CLD growth and metabolism
[78]. During lipolysis, CLD surface area decreases resulting in “protein crowding” and
ultimately the removal of proteins which are more loosely bound to the CLD. The
removal of proteins during CLD shrinkage has the potential to alter CLD composition
and metabolism. Understanding which proteins associate with CLDs during CLD
synthesis, growth, and catabolism remains an active of research [72].
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1.3.1.3 CLD connection with organelles
CLDs are highly connected organelles that physically interact with ER, other
CLDs, mitochondria, and lysosomes [79]. CLDs are thought to emerge from the ER and
may maintain a physical connection or close contact with the ER [80]. The bridge
between ER and CLDs has been suggested to facilitate the transport of proteins and lipids
between the two organelles [49] [81]. This is also a proposed mechanism of CLD growth.
Additionally, CLDs are connected to other CLDs through CIDE proteins. Both CIDEC
and CIDEA localize to CLD contact sites [82, 83]. CLDs are also connected or closely
associated with mitochondria. Fatty acids mobilized from CLD stores can channel to
mitochondria for oxidation [84], although the proteins which mediate the interaction
between the two organelles remain unknown. CLDs are connected to autophagosomes.
Electron microscopy images demonstrate that autophagosomes surround the CLD during
starvation conditions in hepatocytes to mobilize stored TAG [85]. The process of lipid
mobilization through the process of lipophagy will be described later. Recognition of
CLDs as highly connected organelles is transforming the concept of CLDs from mere
lipid storage sites to central players in whole cell metabolism.

1.3.1.4 Roles of CLDs
CLDs store excess energy and help protect cells from free fatty acid induced
cytotoxicity. Tissues specialized in energy storage, such as adipose tissue, can store
incredible amounts of energy in the form of TAG and stored in CLDs. A non-obese
person can store over 500,000 kJ of energy as TAG in CLDs of adipocytes, enough to run
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about 30 marathons [72]. Additionally, CLDs protect cells against toxic effects of free
fatty acids. Excess non esterified free fatty acids or cholesterol can trigger cell membrane
damage and trigger inflammatory responses. When esterified to TAG or CE and stored in
CLDs, excess fatty acids are buffered against the cellular environment and serve as a
source of lipid for cellular processes.
CLDs serve as a source of fatty acids for cell function. Fatty acids mobilized from
CLD stores can be used to provide energy for the cell through oxidation. Fatty acids
mobilized from CLDs can be used to generate complex lipids. Fatty acids can be used for
synthesis of PL, CE, or TAG. CLDs may also serve as a source of fatty acids or other
lipid species functioning as signaling molecules. Adipose triglyceride lipase (ATGL), a
cytosolic lipase that localizes to the CLD, catalyzes the hydrolysis of a FFA from stored
TAG in the lipid droplet. The resulting FFA potentially acts as a ligand for peroxisome
proliferator- activated receptor alpha (PPARa). Liver specific knockdown of ATGL
decreases the expression of PPARa target genes and the effect is reversed when PPARa
agonists are administered [86].
More recently, CLDs have been hypothesized to serve as protein storage sites.
The most well characterized example of CLDs serving as protein depot is during
embryogenesis in Drosphilia. Histones localize to CLDs until needed for cell replication
[87]. Alternatively, CLDs may serve as a site for targeting proteins for degradation. In
particular ApoB has been shown to localize to CLDs and aggregate when proteasomal
degradation is inhibited [88]. Lastly, proteins may transiently localize to CLDs to be
transferred to other organelles [89].
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1.3.1.5 CLD synthesis
CLDs are generated and expand through multiple mechanisms. There are several
proposed models of CLD biogenesis, including ER budding, bicellar excision, and vesicle
formation (reviewed in [90]). The model with the most current support is ER budding. In
the ER budding model, the accumulation of neutral lipids within the ER membrane
bilayer eventually leads to the budding of a CLD, with the cytosolic ER membrane leaflet
forming its PL monolayer. This budding process may be driven solely by lipid
accumulation, or mediated by proteins that bind to the ER membrane. A model of CLD
synthesis with less support, the bicellar model, involves neutral lipid accumulation in the
ER membrane followed by excision of this lipid along with both surrounding membrane
leaflets. The issue with this model is that it would result in a transient hole in the ER
membrane. Another model of CLD synthesis with less support is the formation of CLDs
within bilayer vesicles. This mechanism would be mediated by vesicle formation
machinery of the secretory pathway, and the lipid accumulation could occur either within
the ER or after the vesicle buds. The precise mechanism of CLD synthesis in the small
intestine has not been directly investigated. Once CLDs are formed, they are able to
continue to accumulate TAG and increase in size. One mechanism of CLD growth is
through TAG synthesis locally at the CLD surface [49, 90]. PL synthesis is important for
CLD monolayer expansion in this growth mechanism. A second mechanism for CLD
growth is through fusion of CLDs [90, 91]. Although there is not much known about
CLD growth in enterocytes specifically, it may occur through one or both of these
mechanisms.
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TAG synthesis is known to occur at the ER membrane, but more recently this
process has been observed at the CLD surface and shown to contribute locally to the
growth of CLDs (reviewed in [90]). For this to occur, TAG synthesis machinery needs to
localize to the CLD surface. One isoform of each of the enzymes involved in the G3P
pathway of TAG synthesis (GPAT4, AGPAT3, PAP, and DGAT2) has been shown to
localize to CLDs in either Drosophila S2 cells, 3T3-L1 adipocytes, or COS7 cells [48]
[49] and [92]. In addition, specific isoforms of enzymes that activate FAs to form acylCoAs for incorporation into TAG (ACSL1, ACSL3, and ACSL4) have been identified on
CLDs in several cell types (reviewed in [93]). In enterocytes, TAG synthesis enzymes
that have been identified on CLDs are ACSL3, ACSL4, ACSL5, GPAT3 and MGAT2 in
mice and humans (reviewed in [33] and [94]). Of these, ACSL3 [95], ACSL5 [96], and
GPAT3 [33] have been validated by confocal or electron microscopy to be present on
CLDs in enterocytes.
During CLD growth, additional PLs are required for expansion of the PL
monolayer surrounding CLDs to prevent their coalescence [97]. Phosphatidylcholine (PC)
is the most abundant PL in these structures, and plays an important role in CLD growth
[97, 98]. Three pathways mediate PC synthesis and are present in most cell types. These
pathways include the de novo, or Kennedy pathway, the phosphatidylethanolamine
methyl transferase (PEMT) pathway (liver cells only), and the Lands Cycle.
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1.3.1.6 CLD catabolism
Lipolysis mediates the biochemical hydrolysis of neutral lipids and CLD
catabolism. The biochemical reaction of lipolysis is catalyzed by enzymes that hydrolyze
ester bonds of lipids including TAGs, CEs, and PLs. TAGs are hydrolyzed to glycerol
and FAs, CEs are hydrolyzed to free cholesterol and FAs and PLs are hydrolyzed to
lysophospholipids and FAs. In a cell, lipolysis often refers to the breakdown of CLDs;
however, lipolysis can take place wherever lipids containing ester bonds are present.
Through lipolysis, the neutral lipids in the core of CLDs are able to be mobilized to a
variety of metabolic fates.
There are two identified pathways that mediate lipolysis of CLDs in cells.
Cytoplasmic TAG lipolysis is the most well-known pathway and has been defined
primarily by studies in adipocytes (reviewed in [99]). Lipophagy is a newly-identified
pathway and refers to the selective degradation of CLDs through autophagy (reviewed in
[100]). The enzymes and co-activator involved in cytoplasmic TAG lipolysis and
lipophagy are present and associate with CLDs in multiple cell types.

1.3.1.6.1 Adipose Triglyceride Lipase
ATGL catalyzes the first step of cytoplasmic lipolysis by hydrolyzing an ester
bond in TAG to generate DAG and FA [101]. TAG storage in CLDs inversely correlates
with ATGL activity in enterocytes. In enterocytes of C. elegans, reducing ATGL activity
via RNA interference leads to increased TAG storage in CLDs, whereas increasing

21
ATGL activity by overexpression decreases TAG storage in CLDs [102]. In addition,
whole body Atgl-deficient mice have a severe defect in lipolysis and abnormal
accumulation of TAG in CLDs in many tissues (including enterocytes), and they develop
obesity [103].

1.3.1.6.2 Comparative Gene Identification- 58
CGI-58 is a cofactor that regulates ATGL activity and is present in intestine of
humans, mice and C. elegans. CGI-58 binds to ATGL and is required for efficient ATGL
activity; however, it has no measurable hydrolase activity [104]. Mutations in CGI-58 in
humans cause Chanarin–Dorfman Syndrome [105]. Chanarin–Dorfman Syndrome is a
rare genetic disease resulting in ichthyosis and abnormal lipid accumulation in multiple
tissues including the intestine [106]. CGI-58 also plays an important role in mouse
physiology, including intestinal lipid metabolism. Whole body Cgi-58-deficient mice die
shortly after birth due to a severe skin barrier defect [107].

1.3.1.6.3 Hormone Sensitive Lipase
HSL has broad substrate specificity; but is thought to primarily catalyze the
second step of TAG hydrolysis, the hydrolysis of an ester bond in DAG to generate MAG
and FA. HSL also possesses hydrolytic activity towards TAGs, MAGs, CEs and retinoid
esters, but lacks phospholipase activity [reviewed in [108]). Whole body Hsl-deficient
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mice accumulate DAGs in adipose and non-adipose tissues but do not develop obesity
[109, 110]. The link between HSL deficiency and human disease is not clear; however, a
recent clinical study identified a frameshift mutation in the LIPE gene (encodes HSL)
that reduces adipose tissue lipolysis in both basal and stimulated states [111].

1.3.1.6.4 Monoacylglycerol Lipase
MGL catalyzes the final step of cytoplasmic lipolysis by hydrolyzing MAG to
glycerol and FA. MGL localizes not only to CLDs, but also cell membranes and the
cytoplasm [112]. Beyond hydrolyzing dietary MAG species, MGL also hydrolyzes the
endogenous cannabinoid 2-arachidonylglycerol and is known to regulate cannabinoid
signaling in the central nervous system (reviewed in [113]). Therefore, effects of altered
MGL expression may be due to either TAG hydrolysis or cannabinoid signaling, and are
challenging to differentiate. Mouse models deficient in MGL have a decreased rate of
lipolysis and accumulation of MAG [114].

1.3.1.6.5 Putative methods of CLD catabolism
Several lines of evidence suggest the presence of additional lipases particularly in
non-adipose tissue (Reviewed in [115]). In the liver, ATGL accounts for less than 50% of
TAG hydrolysis [116] and ATGL deficient mice develop hepatosteatosis [103]. Residual
TAG activity in ATGL deficient mice and normal VLDL production suggest the presence
of additional TAG hydrolases in the liver. While putative lipases have been briefly
studied in the liver, very little is known about putative lipases in other cell types.
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1.3.1.6.5.1 Arylacetamide deacetylase
In addition to classical lipases and mediators of autophagy, several putative
lipases have recently been identified. Arylacetamide deacetylase (Aadac) is an enzyme
with mRNA expression in hepatocytes, intestinal mucosa, pancreas, and adrenal glands
[117]. Aadac has sequence homology with hormone sensitive lipase. In the intestine Aada
mRNA levels increased with fenofibrate administration. In the liver Aadac is
characterized as a putative microsomal triglyceride lipase [118]. HuH7.5 cells, a human
hepatoma cell line, expressing a short hairpin RNA targeting Aadac has impaired TAG
lipolysis and VLDL secretion. This data indicates that Aadac may play a role in TAG
lipolysis in non--adipose cell types.

1.3.1.6.5.2 Carboxylesterase
Members of the carboxylesterase family are potential lipases. Carboxylesterase 3
(Ces1d, or triglyceride hydrolyze) has triglyceride hydrolase activity [119]. Liver specific
deletion of Ces3 results in reduced plasma TAG without hepatosteatosis [120]. Other
members of the carboxylesterase family have not been investigated for their role in TAG
lipolysis.

1.3.1.6.5.3 Autophagy
Autophagy is the catabolic process that breaks down cellular components
sequestered within double-membrane organelles called autophagosomes by transporting
them to lysosomes. Emerging studies identify CLDs as a selective substrate for
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autophagy which are delivered by autophagosomes to lysosomes, where lysosomal acid
lipase (LAL) hydrolyzes ester bonds in lipids. This process is referred to as lipophagy
(reviewed in [100]). LAL is expressed ubiquitously and is responsible for hydrolyzing
ester bonds in TAGs and CEs within the lysosome, generating free cholesterol, glycerol
and FAs. Mutations in LAL in humans result in two diseases: Wolman disease (complete
loss of LAL) and CE storage disease (CESD; partial loss of LAL) [121, 122]. Patients
with Wolman disease usually have failure to thrive during infancy due to severe
gastrointestinal issues including vomiting, diarrhea and malabsorption. Massive storage
of TAGs and CEs are observed in the liver and small intestine of these patients[123].
Whole-body Lal-deficient mice have similar features of Wolman disease. These mice can
survive into adulthood, but have a shorter lifespan than wild-type mice [124].

1.3.2

CLD protein in enterocytes

1.3.2.1 Physiological conditions promoting CLDs in enterocytes
CLDs are present in the small intestine when chylomicron synthesis is inhibited
and in response to a high fat meal. CLDs are present in the intestine when there are
deficiencies in proteins involved in chylomicron synthesis including ApoB, Mttp, and
Sar1b result in hypobetalipoproteinemia, abetalipoproteinemia, and chylomicron
retention disease. These diseases are characterized by accumulation of TAG in
enterocytes which results in steatorrhea due to enterocyte turnover. These diseases are
also characterized by low blood lipid (TAG and CHOL) levels, deficiencies in fat soluble
vitamins and essential fatty acids and ultimately failure to thrive. Additionally, CLDs are
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present in the intestine when chylomicron synthesis and release is inhibited by chemical
inhibitors. A commonly used non-ionic hydrophobic surfactant known as Pluronic L-81
reversibly inhibit the transport of intestinal chylomicrons [125]. Pluronic L-81 treated
mice accumulate TAG in enterocytes in response to a meal, however it is not clear if
TAG accumulates in CLD or in other cellular organelles such as the ER or the Golgi.
Lastly, CLDs are transiently present in the intestine after a high fat meal. TAG levels in
enterocytes increase and decrease over time [126].

1.3.2.2 CLD composition
1.3.2.2.1 Neutral and phospholipid composition
CLDs in enterocytes contain neutral lipids, phospholipids, and highly
hydrophobic lipids. Isolated CLDs contain primarily TAG but also cholesterol ester,
diacylglycerol ether, and phospholipid, when Caco-2 cells were exposed to mixed
micelles containing 2 mM sodiumtaurocholate, 0.6 mM oleic acid, 0.2 mM
lysophosphatidylcholine, 0.05 mM cholesterol and 0.2 mM 1-O-octadecyl-rac-glycerol
[127]. In a separate experiment CLDs were isolated from the duodenum after a
cholesterol (2%) and sunflower oil challenge. The lipid content of these isolated CLDs
were analyzed by lipidomics and found to contain triglyceride, cholesterol ester, free
cholesterol, phosphatidylcholine, sphingomyelin, ceramides, free fatty acids and mono
and di-acylglycerols. Not surprisingly, the lipid species found in isolated CLDs
correspond to substrates or products of the enzymes which associate with the CLD [128].
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1.3.2.2.2 Perilipins
Members of the perilipin family associate with CLDs in enterocytes. The first
proteins identified associated with CLDs in enterocytes were members of the PLIN
family, perilipin 2 (Plin2, also adipocyte related protein (ADRP) or adipophilin)) and
Plin3 (also Tip47) [129]. These proteins were investigated because the PLIN family of
proteins is well established to associate with CLDs and regulate lipid storage and
hydrolysis in many cell types [130]. Plin2 and Plin3 are the only members of the family
identified in intestine and are differentially expressed and localize to CLDs in enterocytes
based on specific dietary conditions. Plin3, an exchangeable CLD associated protein,
  



 

                

and is absent from CLDs during fasting, as well as in chronic high-fat fed mice in the fed
state, as determined by immunofluorescence microscopy [129].
The role of Plin2 in dietary fat absorption was further investigated in a Plin2deficient mouse model [131]. Plin2-deficient mice have increased fecal TAG content and
decreased CLDs in jejunum and ileum when fed either low-fat or high-fat diets compared
to wild-type mice. Although the effects of Plin2-deficiency on CM synthesis and
secretion were not investigated, these results indicate that Plin2 plays a role in dietary fat
absorption, and Plin3 cannot fully compensate for the loss of Plin2 in this process.
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1.3.2.3 CLDs may serve multiple roles in the enterocyte
CLDs may protect enterocytes from free fatty acid toxicity[132].CLDs may help
regulate the rate and amount of dietary fat absorption after a meal by serving as a sink
and store of dietary TAG. After a meal, dietary fat can go toward chylomicron synthesis
or toward storage in CLDs. Additionally, CLDs may regulate the length of the post
prandial period by controlling the mobilization of stored TAG for chylomicron synthesis.
CLDs may regulate the rate of steroid synthesis. Several proteins associated with steroid
metabolism have been identified and confirmed on the CLD in enterocytes [94] including
3--     

   -hydroxysteroid dehydrogenase 2

(DHB2), and Oestradiol 17--dehydrogenase 11 (HSD17B11). While the small intestine
is not typically classified as a steroidogenic organ, the presence of steroid hormone
metabolism proteins associated with the CLD suggests local production or metabolism of
steroids.
The FAs or lipids released from enterocyte CLDs have the potential to serve as
signaling molecules that regulate intestinal and/or systemic physiology. These FAs or
lipids may serve as ligands for transcription factors, or substrates for synthesizing
specialized, bioactive lipids that regulate diverse cellular functions. In the small intestine,
FAs and lipids act as ligands for trans     

   !

 ""#!

(see details in Section 5.3). In addition, arachidonic acid is the major FA precursor for
synthesizing eicosanoids (such as prostaglandins, leukotrienes, and other related
molecules) and endocannabinoids (anandamide and 2-arachidonoylglycerol). Eicosanoids
and arachidonic acid metabolites in the intestine have been shown to mediate
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inflammatory processes and play a role in inflammatory bowel disease [133, 134].
Furthermore, endocannabinoids have been shown to activate the endocannabinoid system
by binding to their receptors in the intestine and other cell types, resulting in protective
effects against inflammation [135] and [136], regulation of food intake [137], and
regulation of energy homeostasis [138]. Therefore, the dynamic CLD storage in
enterocytes may be important in the regulation of lipid-mediated signaling pathways.

   

           -oxidation to generate

ATP. Although glutamine and glutamate are the major fuel sources in enterocytes [139141] and intestinal FAO activity is low in fed and fasted states [142, 143], emerging
studies highlight that regulation of intestinal FAO activity has the capacity to alter
enterocyte TAG storage and secretion. Altering FAO in the intestine may influence
systemic FA availability, which could alter postprandial blood TAG levels and/or energy
balance.

1.3.2.4 CLD synthesis
The method of CLD biogenesis in enterocytes is thought to be the result of TAG
accumulation within the ER leaflet. The mechanism through which TAG is partitioned to
chylomicron synthesis or CLD synthesis is unknown however may be influenced by
DGAT1/2 and MGAT2 as reviewed in [37].
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1.3.2.5 CLD catabolism
In enterocytes, the size and number of CLDs increase and then decrease over time
after dietary fat is consumed [126]. This depletion of CLDs over time suggests active
lipolysis during dietary fat absorption. In addition, an in vitro experiment showed that the
cytoplasm exhibits the highest lipolytic activity compared to other fractions in Caco-2
cells [144], indicating that CLD catabolism is an important function of intestinal lipid
metabolism. CLD catabolism may regulate the quantity and rate at which dietary fat is
absorbed.
1.3.2.5.1 Adipose Triglyceride Lipase
Intestine-specific Atgl-deficient (iAtgl-deficient) mice were generated to
investigate the role of ATGL in intestinal TAG metabolism and dietary fat absorption
[145]. iAtgl-deficient mice have reduced TAG hydrolase activity in enterocytes from the
proximal small intestine and increased TAG storage in CLDs compared with wild-type
mice fed either chow or a high fat diet. However, iAtgl-deficient mice have similar TAG
secretion from enterocytes and no fat malabsorption compared to wild-type mice. iAtgldefici   

 

          

 

   

regulating fatty acid oxidation (FAO), oxidative stress response, and cholesterol
absorption in enterocytes compared to wild-             
genes in iAtgl-deficient mice may contribute to their intracellular TAG accumulation, as
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well as their delayed cholesterol absorption. Overall, these results suggest that intestinal
ATGL directs FAs released from TAG stored in CLDs towards oxidation mediated by

 activation, and is not directly involved in CM synthesis for TAG secretion into
circulation.

1.3.2.5.2 Comparative Gene Identification-58
Intestine-specific Cgi-58-deficient (iCgi-58-deficient) mice have a significant
reduction in intestinal TAG hydrolase activity, which results in massive TAG storage in
CLDs in enterocytes compared to wild-type mice when fed chow or a high fat diet [146].
Unlike iAtgl-deficient mice, the TAG accumulation in enterocytes of iCgi-58-deficient
mice leads to steatorrhea, indicating fat malabsorption. In addition, iCgi-58-deficient
mice have lower postprandial blood TAG levels and reduced intestinal FAO activity
compared to wild-type mice. These results suggest that CGI-58 is involved in mobilizing
FAs stored in CLDs that are used for both secretion and oxidation. Recently, lipid droplet
protein 1, a homolog of CGI-58, was identified in enterocytes of C. elegans and found to
activate lipolysis by binding to ATGL during fasting [102].

1.3.2.5.3 Hormone Sensitive Lipase
HSL is expressed along the length of the intestine in mice and primarily regulates
intestinal cholesterol metabolism. Whole body Hsl-deficient mice have mild reductions in
DAG hydrolase activity in the intestine but totally abolished CE hydrolase activity [147].
Mice with intestine-specific HSL deficiency (iHSL-deficient mice) were generated to
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study the role of HSL in intestinal lipid metabolism [148]. iHSL-deficiency has little
effect on TAG metabolism in the intestine. iHSL-deficient mice have similar TAG
secretion into circulation and intracellular lipid species (including TAG, DAG, FA and
PL) in enterocytes compared to wild-type mice. However, HSL-deficiency has a
significant effect on intestinal cholesterol metabolism [148]. iHSL-deficient mice have
higher levels of CEs, enhanced cholesterol uptake and reduced cholesterol biosynthesis in
enterocytes compared to wild-type mice. These results suggest that in the intestine HSL is
not required for TAG metabolism, but plays an important role in CE hydrolysis, which is
required for normal intestinal cholesterol metabolism.

1.3.2.5.4 Monoacylglycerol Lipase
Several mouse models with altered Mgl expression have been generated to study
the role of this enzyme in intestinal lipid metabolism. Whole body Mgl-deficient mice
have significantly less MAG hydrolase activity and massive accumulation of MAG
species in multiple tissues, including small intestine [149, 150]. Whole body Mgldeficient mice are either leaner compared to wild-type mice fed either a low or high fat
diet [149], or of similar body weight with improved glucose tolerance and insulin
sensitivity [150]. In addition, these mice display blunted intestinal TAG secretion without
fat malabsorption, as determined by fecal fat content [149]. They also have reduced
mRNA levels of genes involved in the G3P pathway and increased levels of genes
involved in the MGAT pathway in enterocytes. Overall, the alterations in lipid
metabolism in the absence of Mgl may contribute, in part, to the lean and/or improved
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glucose and insulin sensitivity phenotype observed in these models. Mice with intestinespecific overexpression of MGL (iMgl overexpression mice) have higher intestinal MGL
activity, resulting in decreases in MAG species in the intestine compared to wild-type
mice [151]. iMgl overexpression mice are hyperphagic and have reduced energy
expenditure, which contributes to increased susceptibility to obesity when fed a high fat
diet. This phenotype is probably due to altered endocannabinoid signaling in the intestine
since iMgl overexpression mice have little changes in intestinal lipid metabolism.
Intestinal TAG synthesis, metabolism of MAG into different lipid species, and intestinal
FAO activity are similar in iMgl overexpression mice compared to wild-type mice.
However, iMgl overexpression mice have significantly greater TAG accumulation in the
intestine compared to wild-type mice when fed a high fat diet, but do not have fat
malabsorption, as determined by fecal fat content. Whether this intestinal TAG
accumulation has effects on dietary fat absorption or contributes to the obese phenotype
is unclear.

1.3.2.5.5 Putative methods of CLD catabolism
1.3.2.5.5.1 Carboxylesterase
Members of the carboxylesterase family are putative or potential lipases.
Carboxylesterase 2 is a (Ces2) is a highly expressed esterase in the liver and the intestine
[152]. Recombinant mouse Ces2 demonstrates TAG hydrolase activity and liver lysates
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overexpressing Ces2 have increased TAG hydrolysis [153]. Members of the Ces2 family
have been identified on intestinal CLDs [96, 127] and [95] however the role of Ces2 in
the intestinal lipid metabolism has not been investigated.

1.3.2.5.6 Autophagy
CLDs are catabolized in the enterocyte through autophagy. Lipophagy is
stimulated in Caco-2 cells in response to treatment with lipid micelles, as determined by
the co-localization of TAG and components of autophagy machinery using confocal
microscopy [154]. Although little is known about mechanistic activation and regulation
of lipophagy in enterocytes, inhibition of autophagy initiators/mediators by miRNA and
drug inhibition of LAL result in an increase in TAG storage in CLDs in Caco-2 cells.
Together these results highlight that lipophagy is active and regulates intestinal CLD
metabolism during dietary fat absorption.

1.4

Methods for identifying CLD associated proteins

Methods for identifying CLD associated proteins by either targeted or global
proteomic approaches vary from study to study based on cell type of interest and
endpoint, however have some consistent key features. Briefly, cells are isolated and lysed,
CLDs are isolated via centrifugation, and proteins are identified by Western Blot or
tandem mass spectrometry analysis. Identifying proteins associated with CLDs help
identify regulators of CLD metabolism and expand the model of the role of CLDs in cell
biology and physiology.
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1.4.1

Introduction to identifying CLD associated proteins

There are multiple methods for identifying proteins which associate with CLDs.
In general, these methods fall into one of two categories, targeted and global proteomic
approaches. Both of these approaches depend on isolation of CLDs without
contamination of associated organelles, associated membranes, or non-CLD lipid
containing particles.

1.4.2

Isolation of CLD associated proteins

To identify CLD associated proteins, cells are harvested under conditions where
CLDs are present. The cells are lysed using various lysis methods based on cell type as
described in [155]. The method of cell lysis and homogenization is dependent on the
CLD size and cell type. A French Press or nitrogen bomb can be used to disrupt cells.
Excess force or mechanical shearing may disrupt very large CLDs as found in adipocytes.
The low density of CLDs allows the organelles to float in an aqueous layer after
centrifugation. The speed at which cells are centrifuged is dependent on CLD size. Larger
CLDs may be isolated at much slower speeds than smaller CLDs. In the case of
lipoprotein producing tissues such as enterocytes and hepatocytes, a slower centrifugation
step may allow for the separation of CLDs from lipoprotein sized contaminating particles.
To identify bona fide CLD associated proteins, some investigators wash the isolated CLD
fraction to remove contaminating membranes. This washing process has been shown to
result in the removal of both contaminating proteins as well as reduce the level of bona
fide proteins [156]. Once isolated, the CLD fraction is delipidated and proteins are
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precipitated and prepared for mass spectrometry analysis [Reviewed in[157]] Once a
protein is identified associated with the CLD fraction by mass spectrometry analysis, the
localization of the protein to the CLD should be confirmed using imaging techniques.

1.4.3

Proteomics methods

Proteomic methods for identifying CLD associated proteins fall into two general
categories, targeted and global proteomics.

1.4.3.1 Targeted approach
CLD associated proteins can be identified through a targeted proteomic approach.
This approach involves the analysis of isolated CLD associated proteins by Western Blot
analysis. This approach is cost effective, relatively simple, and does not require special
equipment or analysis software. The downside to a targeted approach is the analysis is
limited by previous knowledge of proteins which are thought to play a role in CLD
metabolism or localize to CLDs.

1.4.3.2 Global approach
CLD associated proteins can be identified through a global proteomic approach.
This approach involves the analysis of CLD associated proteins by mass spectrometry
analysis. This approach is more complex and requires specialized software and analysis
equipment. This approach is more sensitive than traditional Western Blot analysis,
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particularly with modern high resolution mass spectrometers. Within the category of
global proteomics there are two sub classifications, labeled and label free proteomics.
Several labeling methods exist [158] which revolves around using stable isotopes to label
amino acids to quantitatively compare levels of proteins in two or more treatment groups.
Alternatively, quantitative levels of CLD associate proteins can be determined using label
free proteomic approach [159]. This approach utilizes normalization software to
determine the relative levels of a protein in a sample.

1.4.4

Confirmation of CLD associated proteins by imaging

Recent advances in imaging techniques have expanding upon the ability to
visualize CLDs under different physiological conditions and resolutions. Commonly used
microscopy techniques to visualize lipids are fluorphore labeled lipid (ex. BODIPY
labeling of fatty acids), Coherent anti-stokes ramen scattering spectroscopy (CARS), and
transmission electron microscopy. [Reviewed in [160]]. Each technique has benefits and
limitations which should be taken into consideration when interpreting results. A number
of techniques have been employed to visualize the localization of proteins to CLDs
including conjugating proteins to fluorescent tags and conjugating proteins to
fluorescently or gold labeled antibodies for confocal or TEM analysis respectively. High
resolution microscopy is required to determine if a protein localizes to CLDs or
surrounding structures.
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1.5

Recent discoveries and new mysteries of CLD associated proteins

1.5.1

General observation of newly identified CLD associated proteins

A significant body of work has been generated regarding the identification of new
CLD associated protein. Newly identified CLD associated proteins are associated with a
wide range of biological processes and metabolic pathways. These proteins include
various mitochondrial, ER, chaperone, membrane trafficking, and carbohydrate
metabolism related proteins. Non-lipid related proteins have been identified in CLD
proteomic profiles from multiple species and cell types [96, 156, 161-167]. The
identification of the roles of these non-lipid related proteins on the CLD is currently an
understudied and underexplored area of research within the field of CLD biology.

1.5.2

Newly identified CLD associated proteins in enterocytes

The proteomes of isolated CLDs derived from Caco-2 cells and mouse
enterocytes have been analyzed using a tandem mass spectrometry approach [95, 96, 127]
and have been previously reviewed [94]. These studies identified both known and novel
CLD associated proteins. Proteins were categorized based on their gene ontology into
lipid related and non-lipid related proteins. Within the lipid related category, proteins fall
into various sub groupings including: modifiers of FAs, PL synthesis enzymes, lipid
transporters, and steroid synthesis enzymes (Table 1-1). Several of these proteins were
confirmed on the CLD through imaging techniques, including 3-beta-hydroxysteroid
dehydrogenase (3BHS1) [95, 127] , ACSL3 [95], ACSL5 [96], APOA-

    

-
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hydroxysteroid dehydrogenase type 2 (DHB2) [95], and LPCAT2 [95, 127]. It is
currently unclear what function many of these proteins serve on the CLD; however, the
presence of these proteins can be used to generate several intriguing hypotheses.

1.6

Effects of obesity on dietary fat absorption

The effect of obesity on intestinal lipid metabolism is currently unclear, but may be
dysregulated by obesity and associated diseases (recently reviewed [2]). Much of the
research on obesity and blood fat levels have been conducted in the fasted state, however
after work done by Zilversmit et al [168] which correlated increased post prandial
response with an increased risk for atherosclerosis, more attention has been paid to blood
fat in response to a meal. It is often to distinguish between the effect of obesity, and its
comorbidity insulin resistance, on post prandial lipidemia.\

1.6.1

Whole animal/ physiological consequences

Obesity is associated with dyslipidemia in the post prandial state which has been
suggested as a risk factor for coronary artery disease [169]. The small intestine
contributes to blood lipid levels in the post prandial state by secreting chylomicrons. The
level of fat in the blood after a meal is a balance between the secretion of lipoproteins and
clearance by peripheral tissues. The effect of obesity on this balance is relatively
unknown.
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Obese subjects with high levels of visceral adipose tissue had a prolonged or
higher postprandial triglyceride response compared to lean subjects [170-173]. The
authors conclude that the postprandial response was due to in part by the contributions of
liver lipoproteins [170].

1.6.2

Enterocyte specific consequences

Obesity affects lipid metabolism in enterocytes. Duodenal explants from insulin
resistant obese patients had a decreased triglyceride rich lipoprotein production compared
to insulin sensitive obese patients [174]. DIO mice had similar TAG content in intestinal
villi in response to a dietary fat challenge as determined by CARS microscopy compared
to lean mice. Additionally, DIO mice have decreased rate of TAG secretion in response
to a dietary fat challenge [175, 176].
Chronic high-fat diet consumption in mice results in DIO and alters intestinal
CLD metabolism. DIO mice have a reduced TAG secretion rate in response to dietary fat
compared to lean mice [4] and [197]. In the fed state, DIO mice have abundant TAG
storage in CLDs within enterocytes, but after a six hour fast this TAG storage is
significantly reduced. In DIO mice given an acute dietary fat challenge, mRNA levels of
genes involved in lipolysis (Atgl and Hsl) are significantly reduced compared to before
the challenge [4]. This is a response to dietary fat that does not occur in lean mice. These
results suggest that DIO induces adaptations in CLD metabolism resulting in decreased
mobilization of enterocyte TAG stores and decreased TAG secretion.
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1.7

Conclusion

Identifying regulators of intestinal CLD metabolism can provide potential targets
for the prevention and treatment for chronic diseases associated with dyslipidemia
including obesity, Type II Diabetes, and cardiovascular disease (Pirillo 2014) (Patsch
1992). The small intestine is the source of chylomicrons in the post prandial state. The
balance of dietary TAG storage and secretion may regulate post prandial TAG levels. The
proteins that associate with CLDs regulate CLD metabolism and TAG mobilization.
Identifying proteins that associate with CLDs and regulate CLD metabolism are potential
targets for regulating chylomicron lipidation and post prandial hypertriglyceridemia. A
few of the outstanding questions regarding the role of CLDs, and associated proteins in
the regulation of dietary fat absorption that this thesis intends to address are:
1) What proteins associated with CLDs in enterocytes in response to a dietary fat
challenge? (Chapter 2).
2) What effect does obesity have on CLDs and associated proteins? (Chapter 3)
3) What role does Acsl5 play in dietary fat absorption? (Chapter 4)
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Table 1-1 Proteins identified by proteomic analysis associated with CLDs from
enterocytes
.Gene
symbol

Protein name

Biological pathway

Reference

CYB5R3

NADH–cytochrome b5 reductase 3

Cholesterol metabolism

95, 96, 127

DHCR7

Cholesterol metabolism

127

NSDHL

7-Dehydrocholesterol reductase
NAD(P)H steroid dehydrogenase-like
protein

Cholesterol metabolism

95, 127

ACSL3

Long chain acyl-CoA synthetase 3

Fatty acid metabolism

95, 127

ACSL4

Long chain acyl-CoA synthetase 4

Fatty acid metabolism

127

ACSL5

Long chain acyl-CoA synthetase 5

Fatty acid metabolism

95, 96

ECHS1

Enoyl-CoA hydratase, mitochondrial

Fatty acid oxidation

127

Hadh

Hydroxyacyl-coenzyme A dehydrogenase

Fatty acid oxidation

96

Ugt1a7c

UDP-glucuronosyltransferase 1–7C

Hormone metabolism

96

Bpnt1

3(2), 5-bisphosphate nucleotidase 1

Hydrolase

96

Ces2a

Pyrethroid hydrolase

Hydrolase

96

Ces2c

Acylcarnitine hydrolase

Hydrolase

96

Ces2e

Pyrethroid hydrolase

Hydrolase

96

EPHX1

Epoxide hydrolase 1

Hydrolase

127

Ephx2

Bifunctional epoxide hydrolase 2

Hydrolase

96

LDAH

Lipid droplet-associated hydrolase

CGI-58

Comparative gene identification-58

FAF2

FAS-associated factor 2

Lipe

Hormone-sensitive lipase

PLIN2

Perilipin 2/ADRP

PLIN3

B4galnt2

Perilipin 3/TIP47
Patatin-like phospholipase domaincontaining protein 2
Beta-1, 4 N-acetylgalactosaminyltransferase
2

Hydrolase
Lipid droplet
metabolism
Lipid droplet
metabolism
Lipid droplet
metabolism
Lipid droplet
metabolism
Lipid droplet
metabolism
Lipid droplet
metabolism

Scp2

Non-specific lipid-transfer protein

Mogat2

Monoacylglycerol: acylCoA transferase 2

Lipid synthesis

128

Clint

Lipid transport

96

Dbi

Clathrin interactor 1
Diazepam binding inhibitor, Acyl-CoAbinding protein

Lipid transport

96

Fabp1

Fatty acid-binding protein, liver

Lipid transport

96

Fabp2

Fatty acid-binding protein, intestinal

Lipid transport

96

ANXA2

Annexin A2

Lipoprotein metabolism

96, 127

Apoa1

Apolipoprotein A-I

Lipoprotein metabolism

96

PNPLA2

95, 127
127
95, 127
96, 128
95, 127, 128, 129
95, 96, 127, 129
95, 127, 128

Lipid glycosylation

96

Lipid metabolism

96
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Table 1-1 Continued
APOA4

Apolipoprotein A-IV

Lipoprotein metabolism

96, 127

Apob

Apolipoprotein B

Lipoprotein metabolism

96

APOE

Apolipoprotein E

Lipoprotein metabolism

127

MGLL

Monoglyceride lipase

Lipoprotein metabolism

95, 127

MTTP

Microsomal triglyceride transfer protein

Lipoprotein metabolism

95, 96, 127, 128

P4HB

Protein disulphide-isomerase

Lipoprotein metabolism

95, 96, 127

ANXA4

Annexin A4

Membrane metabolism

ELMOD2
DHRS1

ELMO domain-containing protein 2
Dehydrogenase/reductase SDR family
member 1

HSPA8

Heat-shock cognate 71 kDa protein

LPCAT2

Lysophosphatidylcholine acyltransferase 2

PCYT1A

Choline-phosphate cytidylyltransferase A

Prdx6

Peroxiredoxin-6

Atp5a1

ATP synthase subunit alpha, mitochondrial

Atp5b

ATP synthase subunit beta, mitochondrial

Cat

Catalase

Golm1

Golgi membrane protein 1

Miscellaneous
Oxidation-reduction
process
Phospholipid
metabolism
Phospholipid
metabolism
Phospholipid
metabolism
Phospholipid
metabolism
Regulation of lipid
metabolism
Regulation of lipid
metabolism
Regulation of lipid
metabolism
Regulation of lipid
metabolism

Adh1

Alcohol dehydrogenase 1

Retinal metabolism

96

Aldh1a1

Retinal dehydrogenase 1

Retinal metabolism

96

DHRS3

Short-chain dehydrogenase/reductase 3

Retinal metabolism

95, 127

Rbp2

Retinol-binding protein 2

Retinal metabolism

96

RDH10

Retinol dehydrogenase 10

95, 127

SGPL1

Sphingosine-1-phosphate lyase 1

Retinal metabolism
Sphingolipid
metabolism

Cyb5a

Cytochrome b5

Steroid metabolism

96

Cyp2b10

Cytochrome P450 2B10

Steroid metabolism

96

HSD17B11

Oestradiol 17--dehydrogenase 11

Steroid metabolism

95, 96, 127

HSD17B2

Estradiol 17-beta-dehydrogenase 2

Steroid metabolism

95

HSD17B7

3-Oxo-steroid reductase

Steroid metabolism

95, 127

HSD3B1

Steroid metabolism

95, 127

Sult1b1

3--Hydroxysteroid dehydrogenase
Sulfotransferase family cytosolic 1B
member 1

Steroid metabolism

LSS

Lanosterol synthase

Sterol metabolism

95, 127

SQLE

Squalene monooxygenase

Sterol metabolism

95

96, 127
127
95, 96, 127
96, 127
95, 127
127
96
96
96, 127
96
96

127

96
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CHAPTER 2. CHARACTERIZATION OF THE PROTEOME OF CYTOPLASMIC
LIPID DROPLETS IN MOUSE ENTEROCYTES AFTER A DIETARY FAT
CHALLENGE

2.1

Abstract

Dietary fat absorption by the small intestine is a multistep process that regulates the
uptake and delivery of essential nutrients and energy. One step of this process is the
temporary storage of dietary fat in cytoplasmic lipid droplets (CLDs). The storage and
mobilization of dietary fat is thought to be regulated by proteins that associate with the
CLD; however, mechanistic details of this process are currently unknown. In this study
we analyzed the proteome of CLDs isolated from enterocytes harvested from the small
intestine of mice following a dietary fat challenge. In this analysis we identified 181
proteins associated with the CLD fraction, of which 37 are associated with known lipid
related metabolic pathways. We confirmed the localization of several of these proteins on
or around the CLD through confocal and electron microscopy, including perilipin 3,
apolipoprotein A-IV, and acyl-CoA synthetase long-chain family member 5. The
identification of the enterocyte CLD proteome provides new insight into potential
regulators of CLD metabolism and the process of dietary fat absorption.

This work was published in PLOSone
T. D'Aquila, D. Sirohi, J.M. Grabowski, V.E. Hedrick, L.N. Paul, A.S. Greenberg, R.J.
Kuhn, K.K. Buhman, Characterization of the proteome of cytoplasmic lipid droplets in
mouse enterocytes after a dietary fat challenge, PloS one, 10 (2015) e0126823.
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2.2

Introduction

Dietary fat is the most energy dense macronutrient consumed and is required for
the absorption of essential fatty acids and other lipophilic nutrients including fat soluble
vitamins. However, when present in excess, dietary fat increases the risk for chronic
diseases such as cardiovascular disease and obesity [1-4]. Therefore, understanding the
regulators of dietary fat absorption and metabolism is important for both the promotion of
health and prevention of disease.
Dietary fat absorption by the small intestine is a multistep process.
Triacylglycerol (TAG) is hydrolyzed by pancreatic lipase in the intestinal lumen
producing monoacylglycerol and free fatty acids. These digestive products are taken up
by the absorptive cells of the intestine, enterocytes, where they are rapidly resynthesized
to TAG. The TAG is then packaged in the core of a chylomicron for systemic delivery of
nutrients throughout the body [3,5,6]. Alternatively, when fatty acids are present in
excess, the newly synthesized TAG may be incorporated into cytoplasmic lipid droplets
(CLDs) within enterocytes. The size and number of CLDs within enterocytes increases
and then decreases after consumption of dietary fat [7]; however, the factors that regulate
CLD synthesis and catabolism within enterocytes are relatively unknown. The
partitioning of TAG into chylomicrons or CLDs is important for determining the amount
and rate of fatty acids delivered systemically. Therefore, identification of factors that
regulate enterocyte CLD metabolism is important for understanding the overall process
of dietary fat absorption.
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Proteins that associate with CLDs in various cell types have been shown to
regulate the synthesis and catabolism of CLDs [8-11]. Recently, our laboratory identified
two CLD associated proteins, perilipin 2 (Plin2) and perilipin 3 (Plin3), on CLDs within
enterocytes after a dietary fat challenge [12]. These well-established CLD associated
proteins are thought to regulate lipolysis. In addition, mice deficient in mediators of
lipolysis, including adipose triglyceride lipase [13] and abhydrolase domain containing 5
[14], have altered catabolism of CLDs in enterocytes. These results strongly suggest CLD
associated proteins regulate the synthesis and catabolism of CLDs in enterocytes. The
identification of additional CLD associated proteins within enterocytes has the potential
to establish novel mediators of dietary fat absorption.
The objective of this study was to identify CLD associated proteins in enterocytes
after a dietary fat challenge. To fulfill this objective, we isolated CLDs from the small
intestine of mice two hours after an oil bolus and identified proteins involved in the
regulation of lipid trafficking and metabolism using a global proteomic approach. We
further validated the presence of selected proteins on or around CLDs by confocal and
immunoelectron microscopy.
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2.3

Materials and methods

2.3.1

Ethics statement

We conducted the study in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institute of Health.
The protocol was approved by the Purdue Animal Care and Use Committee (PACUC#
1111000154). All effort was made to minimize pain and suffering of mice and the
number of mice used.

2.3.2

Mice

C57BL/6 male mice from an in-house breeding colony were used for this study.
The mice were maintained on a chow diet (PicoLab 5053, Lab Diets, Richmond, IN,
USA) that consisted of 62.1% of calories from carbohydrate (starch), 24.7% from protein,
and 13.2% from fat. The mice were housed in a temperature and humidity controlled
facility with a 12 hour light/dark cycle (6AM/6PM) with ad libitum access to food and
water.

2.3.3

Mouse procedure for lipid droplet isolation and proteomic analysis

Four, 5 month old male C57BL/6 mice were fasted for 4 hours at the beginning of
the light cycle. An oral gavage of 200 µl olive oil was administered and two hours after
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the oil bolus, the mice were euthanized via CO2 asphyxiation. The small intestine was
excised and divided into five equal length segments in relation to the stomach and labeled
sections 1-5. Segments 2 and 3, representing the jejunum, were used for analysis.

2.3.4

Enterocyte Isolation

Enterocytes were isolated from sections 2 and 3 of the small intestine as
previously described [12,15]. Briefly, the intestinal sections were washed in tissue buffer
(Hank's Balanced Salt Solution with 25 mM HEPES and 1% fetal calf serum) and then
placed in isolation buffer (Calcium and magnesium free Hank's Balanced Salt Solution
with 1.5mM EDTA). The intestine segments were incubated for 15 minutes at 37° C with
rotation. The sample was mixed briefly (vortexed) and the supernatant containing
enterocytes was removed and saved. The process was repeated and the supernatants
containing isolated enterocytes were combined.

2.3.5

CLD isolation

CLDs were isolated from enterocytes using a previously established sucrose
gradient ultracentrifugation protocol [16]. Enterocytes were lysed in ice cold sucrose lysis
buffer (175mM sucrose, 10 mM HEPES and 1 mM EDTA pH 7.4). Cells were disrupted
by passing through a 27 gauge, 1 inch needle, eight times. The resulting two mLs of cell
lysate were carefully layered with six mLs of sucrose-free lysis buffer and centrifuged at
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20,000 x g at 4  C for two hours. After centrifugation, the sample was frozen at -80 C.
The frozen sample was sliced into seven sequential fractions which were approximately 1
cm in length.
2.3.6

TAG and protein analysis

TAG concentration of each fraction was determined using an L Type TG M assay
(Wako Diagnostics, Richmond VA, USA). Protein concentration of each fraction was
determined by a BCA assay (Thermo Scientific, Rockford IL, USA). Additionally, a
Western Blot analysis was performed on each fraction. Briefly, samples from the
isolated fractions were delipidated using 10% sodium dodecyl sulfate, separated by
polyacrylamide gel electrophoresis, and transferred to a PVDF membrane. The
membranes were probed overnight at 4 C with antibodies for Plin3 (a gift from Dr. Perry
Bickel at the University of Texas Southwestern, Dallas TX, USA), glyceraldehyde 3phosphate dehydrogenase (Gapdh) (Abcam, Cambridge MA, USA), or calnexin (Cnx)
(Santa Cruz Biotechnology, Dallas TX, USA). These proteins were used as markers for
the CLD, cytosolic, or membrane fractions, respectively. The blots were then probed with
a LI-COR IR DYE 800CW secondary antibody and imaged using Odyssey CLx Infrared
imaging system (LI-COR Biosciences, Lincoln NE, USA).

2.3.7

In solution digestion and LC MS/MS

In preparation for proteomic analysis, the isolated CLD fractions were delipidated
using 2:1 chloroform methanol and proteins precipitated using ice cold acetone. The

63
protein pellet was denatured using 8M urea and 10 mM DTT for 1.5 hours at 37°C. The
sample was digested for 12 hours using trypsin (Sigma-Aldrich, St. Louis MO, USA)
using a ratio of 1 µg trypsin to 50 µg protein. The reaction was quenched using
trifluoroacetic acid. Tryptic peptides were separated on a nanoLC system (1100 Series
LC, Agilent Technologies, Santa Clara, CA). The peptides were loaded on the Agilent
300SB-C18 enrichment column for concentration and the enrichment column was
switched into the nano-flow path after five minutes. Peptides were separated with a C18
reversed phase ZORBAX 300SB-C18 column. The column was connected to the
emission tip and coupled to the nano-electrospray ionization (ESI) source of the high
resolution hybrid ion trap mass spectrometer LTQ-Orbitrap LX (Thermo Fisher Scientific,
Waltham MA, USA). The LTQ-orbitrap mass spectrometer was operated in the datadependent positive acquisition mode in which each full MS scan (30.000 resolving power)
was followed by six MS/MS scans where the six most abundant molecular ions were
selected and fragmented by collision induced dissociation (CID) using a normalized
collision energy of 35%..

2.3.8

Data analysis and bioinformatics

The peak list files containing MS and MS/MS data were analyzed using
MaxQuant version 1.4.08[17]. For protein identification, the MS/MS data was searched
against the Uniprot protein database which includes the Swissprot (manually annotated
and reviewed) and TrEMBL (automatically annotated and not reviewed) databases [18].
The database was searched using the MASCOT search engine utilizing Andromeda as the
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peptide search algorithm that is incorporated in the MaxQuant platform [19]. The search
was conducted using the following settings: trypsin cleavage with a maximum of two
missed cleavages, fixed modification of iodoethanol addition to cysteine, variable
modification of oxidation of methionine. The MS mass tolerance was set at 4.5 ppm with
a maximum number of five modifications. The false discovery rate was set at 0.01 for
proteins and peptides and was run against a decoy revert database. Peptides required a
minimum length of seven amino acids. The MS/MS tolerance was set at 0.1 Da for
protein identification. The minimum score for modified and unmodified peptides was set
at forty. At least two peptides were required for protein identification.
The bioinformatics and statistical package Perseus 1.4.1.3 was used to analyze the
MaxQuant output. Contaminants identified by Perseus, such as keratin, were removed
from the analysis. For label free quantitation (LFQ), the intensity for each protein was
transformed log2(x) and samples who had a peptide intensity below the level of detection
were assigned a value of 14. We limited the analysis to proteins which were identified in
at least 3 out of the 4 biological replicates.
Proteins identified were clustered by their Gene Ontology (GO) Term based on
biological process or molecular function using the Database for Annotation, Visualization
and Integrated Discovery (DAVID) v 6.7 [20,21]. Visualization of protein interactions
was accomplished using STRING version 9.1[22]. We used the confidence view with a
score of 0.4, indicating a medium confidence level. We did not limit the number of
interactions in the analysis.
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2.3.9

Immunofluorescence Imaging

Four, C57BL/6 male mice were fasted for 4 hours at the beginning of the light
cycle and then administered a 200 µl olive oil bolus. A small (5mm) section of the
jejunum was harvested from the mice two hours after the dietary fat challenge and was
frozen in optimal cutting temperature embedding media. The tissue was stored at -80°C
until processed by immunofluorescence microscopy. The tissue was sliced into 10 µm
tissue sections, fixed in 2% paraformaldehyde, and permeabilized with 0.1% saponin.
The tissue was probed with previously validated antibodies for Plin3 [23] (a gift from Dr.
Perry Bickel at the University of Texas Southwestern, Dallas TX, USA), apolipoprotein
A-IV (ApoA-IV) [24] (a gift from Dr. Patrick Tso from the University of Cincinnati,
Reading OH, USA), and acyl-CoA synthetase long-chain family member 5 (Acsl5)
(personal communication with A. Greenberg) (a gift from Dr. Andrew Greenberg from
Tufts University, Boston MA, USA). The sections were also stained for neutral lipids
  

-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene

(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville
NY, USA). Image processing, co-localization analysis, and multidimensional imaging
were conducted using NIS- Elements C acquisition and analysis software.
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2.3.10 Transmission electron microscopy

2.3.10.1 Cardiac perfusion fixation and TEM imaging of jejunum
Two, C57BL/6 mice were fasted for 4 hours at the beginning of the light cycle.
An oral gavage of 200 µl olive oil was administered and two hours after the oil bolus, the
mice were anesthetized using inhaled isoflurane and perfused with 1.5% glutaraldehyde
in 0.1M sodium cacodylate via cardiac infusion. After fixation, a sample of the jejunum
section of the small intestine was isolated, stained with osmium tetroxide, dehydrated,
and embedded in resin. Ultrathin sections were stained with lead citrate and uranyl
acetate and examined using a Tecnai T20 Transmission Electron Microscope (FEI,
Hillsboro OR, USA).

2.3.10.2 TEM imaging of isolated CLDs
A sample from the isolated CLD fraction was negatively stained using 2% w/v
aqueous uranyl acetate. The isolated CLDs were imaged using a Tecnai T20
Transmission Electron Microscope (FEI).

2.3.10.3 Immunoelectron microscopy
Two, C57BL/6 mice were fasted for 4 hours at the beginning of the light cycle.
An oral gavage of 200 µl olive oil was administered and two hours after the oil bolus, the
mice were anesthetized using inhaled isoflurane and perfused with 4% paraformaldehyde
and 0.05% glutaraldehyde in 0.1M phosphate buffer via cardiac infusion. After fixation, a
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sample of the jejunum section of the small intestine was isolated, dehydrated, and
embedded in resin. Ultrathin sections were probed with an antibody for Acsl5 (a gift from
Dr. Andy Greenberg), gold conjugated secondary antibody (Ted Pella Inc. Redding, CA),
and stained with uranyl acetate. The samples were examined using Tecnai T20
Transmission Electron Microscope (FEI).

2.4

2.4.1

Results

Lipid accumulates in CLDs in enterocytes in response to a dietary fat challenge.

Neutral lipids accumulate in distinct regions of the enterocyte following an acute
olive oil bolus. Enterocytes from the jejunum section of the small intestine, two hours
after a dietary fat challenge, were stained with osmium tetroxide and examined by
transmission electron microscopy (Figure 1). The various fates of neutral lipids within
enterocytes following a dietary fat challenge are identified in this image. Neutral lipids
accumulate in large CLDs which are indicated by white asterisks. Also visible is the
Golgi apparatus (white arrows) which contains smaller chylomicron sized particles.
Additionally, the white areas between enterocytes contain secreted chylomicrons (black
cross). These results highlight the complex, multistep process of dietary fat absorption.

2.4.2

The CLD fraction is enriched with Plin3 and has a high TAG to protein ratio.

Enterocyte CLDs were isolated via density gradient ultracentrifugation using a
previously established protocol [16]. After centrifugation, the samples were frozen and
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sliced into seven fractions, where fraction 1 contains CLDs (Figure 2a). To confirm the
successful isolation of CLDs, the isolated fractions were subjected to Western blot
analysis. Antibodies for Plin3, Gapdh, and Cnx, were used as markers of the CLD,
cytosolic, and membrane fractions respectively. The CLD marker Plin3 was found in
fractions 1, 4, 5, 6, and 7 (Figure 2c), representing the various fractions Plin3 has been
previously described to locate [25]. Plin3 is found primarily in the cytosol when lipids are
absent and translocate to the nascent CLD in the early stages of CLD formation. Gapdh
was used as a cytosolic marker and was found primarily in the cytosolic fractions
(fractions 2-6). In addition, Gapdh was notably absent in fraction 1. Cnx was used as a
marker for membranes and found primarily in fraction 7. To validate the presence of
CLDs, the TAG to protein ratio of each fraction was examined (Figure 2b). Fraction 1
contained a high concentration of TAG compared to protein, indicating the presence of
CLDs. Fraction 1 was also examined using negative staining electron microscopy which
showed an abundance of round, CLD sized particles (Figure 2d). This data suggests that
CLDs were successfully isolated from mouse enterocytes.

2.4.3

Proteins were identified in the CLD fraction through LC MS/MS

To identify proteins that associate with the CLD fraction, we utilized a shotgun
proteomic approach. Through high resolution tandem mass spectroscopy, we identified
181 proteins in at least 3 out of the 4 biological replicates (Data not shown). Proteins
were identified by comparing the MS/MS spectra against the Uniprot database. The
Uniprot database combines FASTA files from the Swissprot and TrEMBL databases.
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Using Maxquant’s LFQ [26], the relative abundance of each protein within each sample
was identified. It should be noted that the LFQ intensity is the result of multiple factors,
including the abundance of the protein within the sample and the ability of the peptides to
be ionized and detected. To identify the function of the proteins, we used the functional
annotation tool in DAVID. The Gene Ontology (GO) terms of molecular function and
biological process associated with each protein was identified and then GO terms were
clustered into broader classifications as described in Table 1. The percentage of proteins
categorized within broader classifications is found in Figure 3. On several occasions, the
GO terms associated with a protein would fall under multiple broader classifications.
Under these circumstances, a manual analysis of the protein’s function was conducted
using the Uniprot and NCBI databases. Based on the quantity and quality of reported
protein function, the protein was assigned into the most appropriate GO term and broader
classification.

2.4.4

Some identified proteins in the CLD fraction are associated with known lipid
metabolism related functions

Using DAVID’s functional analysis tool, 19% of the proteins identified in the
CLD fraction were found to be associated with a biological process or molecular function
related to lipid metabolism. The relative abundance of these proteins was determined by
Maxquant’s LFQ (Table 2). Approximately half of these proteins have been identified in
other CLD proteomic studies from diverse cell types (Table 2). We specifically
highlighted proteins which have been previously identified associated with CLDs in an
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intestinal cell model through proteomic analysis. A map of predicted interactions was
generated using a STRING analysis (Figure 4) [22]. The resulting network shows several
protein clusters including proteins responsible for lipoprotein synthesis and modifiers of
fatty acids.
2.4.5

Immunofluorescence imaging of proteins identified in the CLD fraction supports
their CLD localization

To confirm the localization of ApoA-IV and Acsl5 on or around CLDs, we
probed intestinal sections with antibodies for these proteins from four, male C57BL/6
mice, two hours after a 200 µl olive oil bolus. To visualize CLDs, we stained neutral
lipids with BODIPY (Life technologies) and used immunofluorescence staining of a
well-established marker of enterocyte CLDs, Plin3 [12]. Due to the process of fixation,
neutral lipids are often depleted from CLDs; therefore, where applicable, both Plin3 and
neutral lipid staining was used to enhance our ability to detect CLDs. The first protein
investigated was ApoA-IV, a protein known regulate intestinal lipid absorption and
chylomicron synthesis [27,28]. To confirm the localization of ApoA-IV to the area on or
around the CLD, the signals from Plin3 (Figure 5A) and ApoA-IV (Figure 5B) were
merged and overlaid with signals from nuclei (blue) and neutral lipid (orange) (Figure
5C). A region of interest was highlighted (white capped line) in Figure 5C. The intensity
profile of all fluorescent signals along this line was generated (Figure 5D). The intensity
signals from Plin3 and ApoA-IV overlap and form two peaks which flank the signal from
neutral lipids. Additionally, the signal from ApoA-IV and Plin3 antibodies colocalize
with a Pearson’s coefficient of r= 0.59 and a Mander’s overlap of r= 0.96 which indicates
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a high degree of correlation. This indicates that ApoA-IV localizes to the area on or
around the CLD. A three dimensional volume view was generated from Z-series images
(Figure 5E) and illustrates the localization of Plin3 and ApoA-IV to the area on or around
the CLD forming a protein coat. The intensity profile, colocalization analysis, and
volume view was generated using NIS- Elements C software.
The proteomic analysis of isolated CLDs also identified Acsl5, an enzyme that
activates fatty acids by the addition of coenzyme A [29]. In this experiment, we were
unable to use Plin3 as a marker for CLD due to the fact the antibodies for Acsl5 and Plin3
were generated in the same host species, so CLDs are identified using only BODIPY.
Intestinal sections were probed with an antibody for Acsl5 (green) (Figure 6a), stained for
neutral lipids using BODIPY (orange) and nuclei using DAPI (blue) (Figure 6B). Acsl5
forms distinct ring like structures on or around CLDs as indicated by the white arrows. A
3D volume view was generated from Z series images (Figure 6C) showing the
localization of Acsl5 to the area on or around CLDs. Additionally, to confirm the
localization of Acsl5 to CLDs in enterocytes following a 200 µl olive oil bolus, we
performed immunogold labeling of ultra-thin sections of the jejunum section of the small
intestine. An electromicrograph (Figure 6D) shows an enterocyte with large white CLDs
present. Areas of interest are highlighted by colored arrows which correspond with
figures 6 E-H. Acsl5 conjugated gold particles are found on the CLD surface which are
indicated by the white arrows (Figure 6E-G). In figure 6E, Acsl5 can be seen localized to
the CLD as opposed to the endoplasmic reticulum membrane which can been seen on the
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left hand side of the CLD. Additionally, Acsl5 can be found localized to the mitochondria
(Figure 6H) which has been previously reported in Caco-2 cells[30,31] and liver
McArdle-RH7777 cells[32].
2.5

Discussion

To increase our understanding of the process of dietary fat absorption, we
investigated a key step of this process, the storage of dietary fat in CLDs. Proteins
associated with CLDs are likely involved in both the storage and trafficking of fatty acids
as well as other cellular processes. Therefore, we analyzed the proteome of CLDs from
enterocytes isolated from the jejunum section of the small intestine following an oil bolus
using high resolution tandem mass spectroscopy. We identified 181 proteins associated
with the CLD fraction (Data not shown) that are associated with a wide range of
biological and molecular functions (Figure 3). Several of the identified proteins
associated with lipid metabolism have been previously identified in other CLDs
proteomic analyses from many cell types, while other identified proteins have not been
previously reported (Table 2). Furthermore, we confirmed the localization of select
proteins through immunohistochemistry and immunoelectron microscopy (Figures 5 and
6).
Of the 181 proteins identified in the CLD fraction of mouse enterocytes, thirty
seven proteins are associated with known lipid related processes. Within this subgroup,
twenty three proteins (62%) have been identified in CLD proteomic analyses in various
cell types and fourteen proteins (38%) have not been previously reported in CLD
proteomic analyses from any cell type (Table 2). Interestingly, three of the CLD proteins,
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ApoA-IV, Acsl5, and microsomal triglyceride transfer protein (Mttp), have been
previously identified in a human cell model of enterocytes, Caco-2 cells, but not other
cell types [33,34]. Therefore, these proteins may be unique to the CLD of enterocytes
and serve a function on CLDs in dietary fat absorption not previously recognized. We
confirmed the localization of ApoA-IV and Acsl5 on or around CLDs through
immunohistochemistry and immunoelectron microscopy analysis of mouse enterocytes
after a high fat challenge.
ApoA-IV may play important roles in dietary fat absorption due to its localization
on lipoproteins and CLDs [33,35]. Both lipoproteins and CLDs function as lipid storage
vesicles and are surrounded by a phospholipid monolayer and a diverse array of proteins
[3,36]. Many of these proteins regulate synthesis and catabolism of these similar
structures. Therefore, the identification of common proteins on lipoproteins and CLDs is
not surprising. We observed ApoA-IV forming a distinct ring like structure around CLDs
and co-localizing with Plin3, an established CLD protein, through immunofluorescence
imaging. Consistent with this result, ApoA-IV was also identified on CLDs in Caco-2
cells via immunoelectron microscopy [33]. Although the precise function of ApoA-IV
on lipoproteins is not clear, expression of ApoA-IV regulates lipoprotein synthesis and
satiety. When over-expressed, ApoA-IV increases TAG secretion from the liver and
intestine, by increasing the amount of lipid packaged on apolipoprotein B (ApoB)
containing lipoprotein particles [37-40]. Furthermore, ApoA- IV regulates feeding
behavior by trafficking to the brain and serving as a satiety signal [41]. Current
knowledge of ApoA-IV’s role in lipoprotein metabolism can be applied to the formation
of hypotheses regarding the role of ApoA-IV on CLDs. ApoA-IV may regulate CLD
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synthesis and/or regulate satiety through sequestration of the protein on the CLD. These
hypotheses remain to be tested.
Although the identification of lipoprotein associated proteins in the CLD fraction
is not surprising, it is important to consider the potential for contamination of the CLD
fraction by lipoproteins. To minimize contamination of the CLD fraction by smaller, lipid
containing particles the samples were centrifuged at a relatively low speed (20,000 x g).
Smaller lipid containing particles such as lumenal lipid droplets, pre-chylomicron
transport vesicles, and chylomicrons, are isolated at much faster centrifugation speeds,
106,000 x g [42], 100,000 x g [43], and 197,000 x g [44], respectively. Despite efforts to
minimize lipoprotein contamination, we still identified several proteins which are
established for association with lipoproteins including ApoA-IV, ApoB, and Mttp. This
observation is consistent with other CLD proteomic analyses from a range of cell types
that have also identified lipoprotein associated proteins [33,45], including cell types not
known to produce lipoproteins [46,47]. Furthermore, ApoA-IV and ApoB were
demonstrated to localize to CLDs through immunoelectron microscopy in Caco-2 cells
[33] and hepatocytes [48] respectively. Together, these results support that a protein may
be associated with both lipoproteins and CLDs.
Acsl5 may play a role in localized TAG synthesis on CLDs in enterocytes as part
of the process of dietary fat absorption. It was recently demonstrated in lipid challenged
Drosophilia S2 cells that TAGs synthesis enzymes localize to CLDs including glycerol-3phosphate acyltransferase 4, 1-acyl-sn-glycerol-3-phsophate acyltransferase gamma, and
diacylglycerol acyltransferase 2 [11]. In the intestine, two TAG synthesis enzymes that
catalyze the committed step in TAG biosynthesis, diacylglycerol acyltransferase 1 and
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diacylglycerol acyltransferase 2 were identified as associated with CLDs by western
blotting [49]. Additionally, Acsl enzymes activate fatty acids and channel them towards
specific metabolic fates within cells [50]. Interestingly, other Acsl family members
including Acsl1 [45,46], Acsl3 [33,34,46], and Acsl4 [33,46] have been identified on
CLDs in various cell types. In particular, Acsl3 over-expression in Cos-1 cells results in
generation and expansion of CLDs in response to fatty acids [51]. Finally, Acsl5 directs
exogenous fatty acids toward TAG synthesis in hepatocytes [32,52]. Therefore, one
hypothesis for the function of Acsl5 on CLDs in enterocytes is the activation of fatty
acids for TAG synthesis; however, this hypothesis remains to be tested.
A limitation to a proteomic approach for identifying CLD associated proteins is
the challenge to distinguish protein contamination from other cellular organelles from
bona fide CLD proteins in the isolated CLD fraction. It is possible that proteins from
other organelles associate with the CLD fraction nonspecifically during cell lysis because
of the normal tight association of CLDs with other organelles [53]. Methods described in
the literature for isolation of CLDs vary in how cells are lysed and the type and numbers
of washes used. Currently there is not one commonly accepted method for CLD isolation
to alleviate this problem. CLD isolation protocols involving multiple washing steps
remove proteins known to associate with other organelles, as well as decrease the levels
of well-established CLD proteins [45]. In the current study, we used a single step
isolation protocol to preserve potentially loosely bound CLD proteins and reduce the risk
of missing key players in CLD metabolism. However, we only included proteins
identified in 3 of 4 biological replicates to rule out random contamination. Due to these
limitations, each protein identified needs to be validated by other methods such as

76
imaging to confirm the localization to CLDs in enterocytes before making firm
conclusions. Despite these limitations, the identification of Acsl5 on CLDs, ER, and
mitochondria highlights that a single protein may have multiple associations in the cell.
The protein list generated here is intended to be used as an informed, hypothesis
generating tool to prioritize future research, not as a list of established proteins on CLDs
in enterocytes.
The proteins identified in the current study build upon an existing body literature
of CLD biology, from which interesting commonalities are being observed. A key feature,
of all CLD proteomic analyses from multiple cell types, is the identification of non-lipid
related proteins in the CLD fraction. These proteins fall into a wide range of biological
and molecular functions such as amino acid metabolism, carbohydrate metabolism, and
membrane trafficking (Figure 3) [33,34,45-47,54-58]. This consistent observation has not
been fully investigated and remains an intriguing paradox of CLD biology. Several
hypotheses have been proposed to address this issue including the role of CLDs as
sequestration sites [59,60] or in the regulation of membrane trafficking [61]. The
identification of non-lipid related protein in the CLD fraction has expanded our
perception of the CLD from a simple lipid storage site to a complex and multi-functional
organelle [62].
We successfully isolated CLDs from the jejunum of mice after a dietary fat
challenge and identified the proteome of the CLDs. Similar to previously reported CLD
proteomic analyses, the proteins identified in the CLD fraction are associated with a wide
range of biological processes and molecular functions. Of interest, ApoA-IV and Acsl5
were identified in the proteomic analysis of the CLD fraction and the presence was
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confirmed through immunofluorescence and immunoelectron microscopy. The role of
many of these lipid related proteins on the CLD is currently unknown, however the
proteomic analysis provides a foundation to further investigate the role of these proteins
and advance the model of dietary fat absorption and lipid trafficking in the small intestine.
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Table 2-1 GO Terms associated with protein classification term.
GO terms of biological process and molecular function were grouped under broader
classifications. Proteins were assigned into a broader classifications based on the
associated GO terms.
Classification

GO_id

GO Term

Translation

GO:0006412
GO:0006417
GO:0044275
GO:0016052
GO:0044262
GO:0030246
GO:0016051
GO:0030029
GO:0051015
GO:0008092
GO:0006629
GO:0044255
GO:0008289
GO:0019216
GO:0016042
GO:0005811
GO:0016788
GO:0008104
GO:0032880
GO:0015031
GO:0019538
GO:0071822
GO:0042803
GO:0006461
GO:0032403
GO:0051246
GO:0022613
GO:0051252
GO:0006403
GO:2001141
GO:0006396
GO:0055114
GO:0045454
GO:0051920

Translation
regulation of translation
cellular carbohydrate catabolic process
carbohydrate catabolic process
cellular carbohydrate metabolic process
carbohydrate binding
carbohydrate biosynthetic process
actin filament-based process
actin filament binding
cytoskeletal protein binding
lipid metabolic process
cellular lipid metabolic process
lipid binding
regulation of lipid metabolic process
lipid catabolic process
lipid particle
hydrolase activity, acting on ester bonds
protein localization
regulation of protein localization
protein transport
protein metabolic process
protein complex subunit organization
protein homodimerization activity
protein complex assembly
protein complex binding
regulation of protein metabolic process
ribonucleoprotein complex biogenesis
regulation of RNA metabolic process
RNA localization
regulation of RNA biosynthetic process
RNA processing
oxidation-reduction process
cell redox homeostasis
peroxiredoxin activity

Carbohydrate

Cytoskeletal

Lipid

Protein
localization
and transport
Protein
folding and
metabolism

RNA and
transcription

Redox

Number of
proteins
22
5
8
11
11
9
6
12
5
11
21
18
17
10
7
6
10
18
6
15
47
23
19
18
17
16
12
17
4
15
14
27
4
3
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Table 2-2 A sub group of proteins are associated with known lipid related functions.
Thirty seven proteins associated with known lipid metabolism pathways were identified,
of which twenty three proteins have been previously identified in other CLD proteomic
analyses. Relative levels of the proteins were determined by LFQ and the average is
reported (n=4 mice).
Avg
LFQ

Protein name

Gene name

Uniprot
IDs

Identified in
other CLD
studies

Acsl5

Q8JZR0

20.926
20.006

Long-chain-fatty-acid--CoA
ligase 5
Alcohol dehydrogenase 1
Retinal dehydrogenase 1

Adh1
Aldh1a1

Q3UKA4
P24549

21.008

Annexin A2

Anxa2

P07356

21.993
23.367
24.529
18.634

Annexin A4
Apolipoprotein A-I
Apolipoprotein A-IV
Apolipoprotein B
ATP synthase subunit alpha,
mitochondrial
ATP synthase subunit beta,
mitochondrial
Beta-1,4 Nacetylgalactosaminyltransferase
2
3(2),5-bisphosphate
nucleotidase 1
Catalase
Carboxylesterase 2a
Carboxylesterase 2c
Carboxylesterase 2e
Clathrin interactor 1
Cytochrome b5

Anxa4
Apoa1
Apoa4
Apob

Q7TMN7
Q3V2G1
Q9DBN0
E9Q414

Atp5a1

Q03265

[45,47]

Atp5b

P56480

[45,47]

B4galnt2

Q09199

Bpnt1

Q9Z0S1

Cat
Ces2a
Ces2c
Ces2e
Clint1
Cyb5a

Q8C6E3
Q8QZR3
Q91WG0
Q8BK48
Q5SUH7
P56395

21.801

19.522
22.053
18.834
19.963
19.926
18.289
20.492
23.281
16.681
22.123

Identified in
intestine
model
[34]

[45,54,55,58]
[45]
[46,47,55,58,
63]
[47]
[45-47]

[33]
[33]
[33]

[45,64]

[45,47]
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Table 2-2: Continued
22.653
20.515
21.318
19.61
23.106
22.526
18.818

Cyb5r3
Cyp2b10
Dbi
Ephx2
Fabp1
Fabp2
Golm1

Q9DCN2
Q9WUD0
Q548W7
Q3UQ71
Q3V2F7
Q53YP5
Q91XA2

[47]
[45]
[45]

Hadh

Q61425

[46]

21.474

NADH-cytochrome b5 reductase 3
Cytochrome P450 2B10
Acyl-CoA-binding protein
Bifunctional epoxide hydrolase 2
Fatty acid-binding protein, liver
Fatty acid-binding protein, intestinal
Golgi membrane protein 1
Hydroxyacyl-coenzyme A
dehydrogenase
Estradiol 17-beta-dehydrogenase 11

Hsd17b11

Q9EQ06

18.527

Hormone-sensitive lipase

Lipe

P54310

[45,46]
[46,47,56
,57]

18.524

Mttp

O08601

20.812

Microsomal triglyceride transfer
protein
Nucleoside diphosphate kinase

Nme2

Q01768

25.467

Perilipin-3

Plin3

Q9DBG5

19.272
18.859
20.936

Peroxiredoxin-6
Retinol-binding protein 2
Non-specific lipid-transfer protein
Sulfotransferase family cytosolic 1B
member 1
UDP-glucuronosyltransferase 1-7C
Transitional endoplasmic reticulum
ATPase

Prdx6
Rbp2
Scp2

Q6GT24
Q08652
P32020

Sult1b1

Q9QWG7

Ugt1a7c

Q6ZQM8

Vcp

Q8BNF8

23.765

19.562
21.097
18.177

[45]

[33,34]

[33,34]
[33,34]
[33,34]

[46,56,58
,64-66]
[45]
[45,46]

[45-47]

[33,34]
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CHAPTER 3. DIET INDUCED OBESITY ALTERS CYTOPLASMIC LIPID
DROPLET MORPHOLOGY AND ASSOCIATED PROTEINS IN RESPONSE TO
AN ACUTE DIETARY FAT CHALLENGE

3.1

Abstract

Dietary fat absorption by the small intestine is an efficient, multistep process that
regulates the uptake and delivery of essential nutrients and energy. Fatty acids taken up
by enterocytes, the absorptive cells of the small intestine, are resynthesized into
triacylglycerol (TAG) and either secreted in chylomicrons or temporarily stored in
cytoplasmic lipid droplets (CLDs). Proteins that associate with CLDs are thought to
regulate the dynamics of TAG storage and mobilization. It is currently unclear what
affect diet induced obesity (DIO) has on the balance between dietary fat storage and
secretion. Specifically, there is limited knowledge of how DIO affects the level and
diversity of proteins that associate with CLDs and regulate CLD dynamics. In the current
study, we characterize CLDs from lean and DIO mice through histological and proteomic
analyses. We demonstrate that DIO mice have larger intestinal CLDs compared to lean
mice in response to dietary fat. Additionally we identified 375 proteins associated with
CLDs in lean and DIO mice. We identify a subgroup of lipid related proteins which are
either increased or unique to the DIO CLD proteome. These proteins are involved in
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steroid synthesis pathways, TAG synthesis, and lipolysis. This analysis expands upon our
knowledge of the effect of DIO obesity on the process of dietary fat absorption in the
small intestine.
3.2

Introduction

Enterocytes, the absorptive cells of the small intestine, are responsible for the
uptake, repackaging, and secretion of dietary fat. In addition, enterocytes are capable of
temporarily storing dietary fat in CLDs in response to a dietary fat challenge (Reviewed
in [1, 2]) Dietary fat in the form of TAG is digested in the lumen of the small intestine
producing FFA and MAG which are incorporated into mixed micelles. Mixed micelles
interact with the brush border membrane of enterocytes and FFA and MAG are taken up
by enterocytes. In the enterocyte FFA and MAG are resynthesized into TAG by MGAT
and DGAT at the ER. The resulting TAG can be packaged onto a chylomicron particle
for secretion or temporarily stored in CLDs.
CLDs are composed of a neutral lipid core, a phospholipid monolayer, and
associated proteins [3]. Proteins which associate with CLDs are thought to regulate the
storage and mobilization of TAG. Proteins associated with CLDs isolated from
enterocytes after a lipid challenge have been identified by targeted [4] and global
proteomic [5-7] approaches. These studies have identified and confirmed members of the
perilipin family (Plin2 and Plin3) associated with CLDs. Interestingly, these studies have
also identified proteins associated with a wide variety of biological pathways including
lipid catabolic and anabolic pathways.
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Obesity alters the process of dietary fat absorption. The effect of obesity on
intestinal lipid metabolism is currently unclear, but may be dysregulated by obesity and
associated diseases (recently reviewed [8]). Recent studies in high fat diet fed (non obese),
ob/ob mice, and DIO mice have demonstrated decreased TAG secretion rates in response
to an acute dietary fat challenge, when lipoprotein lipase has been inhibited with
tyloxapol [9, 10]. Inhibition of lipoprotein lipase blocks the clearance of lipoproteins
resulting in a dramatic increase in blood TAG levels. DIO alters intestinal mRNA levels
of proteins involved in chylomicron assembly, TAG synthesis, and fatty acid trafficking
[10].
Little is known on the effect of obesity on CLD morphology and associated
proteins in enterocytes. DIO alters CLD associated proteins in adipocytes and
hepatocytes [11, 12].Little is known on the effect of obesity on the CLD proteome in
enterocytes. Previous studies have shown alterations in mRNA levels of proteins known
to associate with CLDs including lipases [10] and members of the perilipin family[13].
Plin2 and 3 localize to CLDs in response to a dietary fat challenge, however under
different physiological conditions. Plin3 localizes to CLDs in response to an acute dietary
 

 



       





 

 



 

Plin2 localizes to CLDs in response to chronic high fat feeding in a DIO mouse model
[13]. A comprehensive analysis of proteins associated with CLDs from lean and DIO
mice in response to an acute dietary fat challenge has not been conducted
`

To determine the effects of DIO on enterocyte CLD morphology and associated

proteins in response to consumption of an acute dietary fat challenge, we investigated
CLDs within enterocytes of lean and DIO mice given an oil bolus orally by transmission
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electron microscopy, immunofluorescence microscopy, and proteomic analysis. Based on
previous observations [9, 10, 13] of altered TAG secretion in DIO mice in response to a
dietary fat challenge, we hypothesized that DIO mice have altered CLD morphology and
CLD associated proteins.

3.3

Materials and methods

3.3.1

Mice

C57BL/6 male mice from an in-house breeding colony were used for this study.
The mice were maintained on a chow diet (PicoLab 5053, Lab Diets, Richmond, IN,
USA) that consisted of 62.1% of calories from carbohydrate (starch), 24.7% from protein,
and 13.2% from fat from weaning to 5 weeks of age. The mice were housed in a
temperature and humidity controlled facility with a 12 hour light/dark cycle (6AM/6PM)
with ad libitum access to food and water.

3.3.2

Generation of DIO mouse model

C57BL/6 male mice were placed on a either high fat diet or low fat diet. The high
fat diet (D12492, Research Diet, New Brunswick, NJ, USA) consists of 20% of calories
from carbohydrates, 20% from protein, and 60% from fat. The low fat, D12492 matched
diet (D12450J, Research Diet, New Brunswick, NJ, USA) consists of 70% of calories
from carbohydrates, 20% from protein, and 10% from fat. The mice were maintained on
the diet for 12 weeks and body weights were monitored weekly.
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3.3.3

Mouse procedure for lipid droplet isolation and proteomics analysis

Five mice from the low fat diet group and 5 mice from the high fat diet group
were

  

    



 

  

   

      

oil was administered and two hours after the oil bolus, the mice were euthanized via CO2
asphyxiation. The small intestine was excised and divided into three equal length
segments in relation to the stomach. The middle segment, representing the jejunum, was
used for the analysis.

3.3.4

Enterocyte isolation

Enterocytes were isolated from the middle section of the small intestine as
previously described [13, 14]. Briefly, the intestinal sections were washed in tissue buffer
(Hank's Balanced Salt Solution with 25 mM HEPES and 1% fetal calf serum) and then
placed in isolation buffer (Calcium and magnesium free Hank's Balanced Salt Solution
with 1.5mM EDTA). The intestine segments were incubated for 15 minutes at 37°C with
rotation. The sample was mixed briefly (vortexed) and the supernatant containing
enterocytes was removed and saved. The process was repeated and the supernatants
containing isolated enterocytes were combined.

3.3.5 CLD isolation

CLDs were isolated from enterocytes using a previously established sucrose
gradient ultracentrifugation protocol [7]. Enterocytes were lysed in ice cold sucrose lysis
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buffer (175mM sucrose, 10 mM HEPES and 1 mM EDTA pH 7.4). Cells were disrupted
by passing through a 27 gauge, 1 inch needle, eight times. The resulting two mLs of cell
lysate were carefully layered with six mLs of sucrose-free lysis buffer and centrifuged at
20,000 x g at 4°C for two hours. After centrifugation, the sample was frozen at -80°C.
The frozen sample was sliced into seven sequential fractions which were approximately 1
cm in length.

3.3.6

In solution digestion and LC MS/MS

In preparation for proteomic analysis, the isolated CLD fractions were delipidated
using 2:1 chloroform methanol and proteins precipitated using ice cold acetone. The
protein pellet was denatured using 8M urea and 10 mM DTT for 1.5 hours at 37°C. The
sample was digested for 12 hours using trypsin (Sigma-Aldrich, St. Louis MO, USA)
   

 

          

trifluoroacetic acid. Tryptic peptides were separated on a nanoLC system (1100 Series
LC, Agilent Technologies, Santa Clara, CA). The peptides were loaded on the Agilent
300SB-C18 enrichment column for concentration and the enrichment column was
switched into the nano-flow path after five minutes. Peptides were separated with a C18
reversed phase ZORBAX 300SB-C18 column. The column was connected to the
emission tip and coupled to the nano-electrospray ionization source of the high resolution
hybrid ion trap mass spectrometer LTQ-Orbitrap LX (Thermo Fisher Scientific, Waltham
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MA, USA). The LTQ-orbitrap mass spectrometer was operated in the data-dependent
positive acquisition mode in which each full MS scan (30.000 resolving power) was
followed by six MS/MS scans where the six most abundant molecular ions were selected
and fragmented by collision induced dissociation (CID) using a normalized collision
energy of 35%..

3.3.7

Protein identification

The peak list files containing MS and MS/MS data were analyzed using
MaxQuant version 1.4.08 [15, 16]. For protein identification, the MS/MS data was
searched against the Uniprot protein database[17]. The database was searched using the
MASCOT search engine utilizing Andromeda as the peptide search algorithm that is
incorporated in the MaxQuant platform [18]. The search was conducted using the
following settings: trypsin cleavage with a maximum of two missed cleavages, fixed
modification of iodoethanol addition to cysteine, variable modification of oxidation of
methionine and acetylation of the N-terminal. The MS mass tolerance was set at 4.5 ppm
with a maximum number of five modifications. The false discovery rate was set at 0.01
for proteins and peptides and was run against a decoy revert database. Peptides required a
minimum length of seven amino acids. The MS/MS tolerance was set at 0.1 Da for
protein identification. The minimum score for modified and unmodified peptides was set
at forty. At least two peptides were required for protein identification. The bioinformatics
and statistical package Perseus 1.4.1.3 was used to analyze the MaxQuant output.
Contaminants identified by Perseus, such as keratin, were removed from the analysis. For
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label free quantitation (LFQ), the intensity for each protein was transformed log2(x). A
protein was considered identified in a treatment group if it was identified in at least 3 out
of the 5 biological replicates.

3.3.8

Data analysis and bioinformatics

The Gene Ontology (GO) Terms for biological process associated with identified
proteins were determined using Gene Ontology Enrichment Analysis and Visualization
Tool (GOrilla) [19, 20]. Visualization of enriched GO terms was accomplished using
GOrilla comparing the isolated CLD proteomic profile to the entire mouse proteome
obtained from the Uniprot protein database. The p value threshold was set at p< .01.
Lipid related GO terms were identified and proteins associated with the lipid related GO
terms were compiled and are here on referred to as “Lipid related proteins”. Visualization
of protein interactions was accomplished using STRING version 10.0 [21]. We used the
confidence view with a score of 0.4, indicating a medium confidence level.

3.3.9

Immunofluorescence imaging

Four mice from low fat diet treatment group and the high fat treatment group were
  

    



 

  

            

oil bolus. A small (5mm) section of the jejunum was harvested from the mice two hours
after the dietary fat challenge and was frozen in optimal cutting temperature embedding
media in 2-methyl butane cooled with dry ice. The tissue was stored at -80°C until
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sections, fixed in 2% paraformaldehyde, permeabilized with 0.1% saponin, and blocked
with 3% bovine serum albumin in PBS. The tissue was probed with previously validated
antibodies for Plin3 [22] (a gift from Dr. Perry Bickel at the University of Texas
Southwestern, Dallas TX, USA) and Plin2 [22]. The sections were also stained for neutral
  



-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene

(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville
NY, USA). Image processing was conducted using NIS- Elements C acquisition and
analysis software.

3.3.10 Cardiac perfusion, fixation, and transmission electron microscopy

Three mice from low fat diet treatment group and high fat treatment group, were
 

             

  

was administered and two hours after the oil bolus, the mice were anesthetized using
inhaled isoflurane and perfused with 1.5% glutaraldehyde in 0.1M sodium cacodylate via
cardiac infusion. After fixation, a sample of the jejunum section of the small intestine was
isolated, stained with osmium tetroxide, dehydrated, and embedded in resin. Ultrathin
sections were stained with lead citrate and uranyl acetate and examined using a Tecnai
T20 Transmission Electron Microscope (FEI, Hillsboro OR, USA).
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3.3.11 Cytoplasmic lipid droplet size analysis

Thirty cells were examined from (n=3 mice) from each treatment group. The cells
analyzed were located in the middle section of the villi and at least 3 villi were measured
per mouse. CLD diameter was measured using ImageJ. Image stitching was performed
using Autostitch.. Data is expressed as mean ± SEM. Statistical significance was
determined using a Type 3 mixed model for fixed effects using SAS v 9.4; P<0.05 was
considered significant. Lipid droplet size distribution was analyzed by two-sample
Kolmogorov–Smirnov test; P<0.05 was considered significant.

3.4

3.4.1

Results

Lipid accumulates in CLDs in enterocytes in response to an acute dietary fat
   

                  

lean and DIO mice

Neutral lipids accumulate in CLDs in enterocytes of the jejunum section of the
small intestine in lean and DIO mice in response to an acute dietary fat challenge (Fig 1).
The representative micrographs highlight the size disparity of CLDs that accumulate in
enterocytes of lean (Figure 1A) compared to DIO mice (Figure 1B).
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3.4.2

CLDs in enterocyte of DIO mice are larger and have a different size distribution
compared to lean mice in response to an acute dietary fat challenge

The average CLD diameter was measured from 30 cells per mouse (n=3 mice)
from each treatment group. No difference was observed in the number of CLD per cell in
lean and obese mice in response to an acute dietary fat challenge (Figure 2a). DIO mice
(black bars) have significantly greater CLD diameter compared to lean mice in response
to an acute dietary fat challenge (Figure 2b). CLDs in enterocytes from DIO mice have a
statistically significant size distribution compared to lean mice in response to an acute
dietary fat challenge as determined by two-sample Kolmogorov–Smirnov test (Figure 2c).

3.4.3

Proteins were identified associated with isolated CLDs from lean and DIO mice in
response to an acute dietary fat challenge

To identify proteins which may contribute to the size distribution disparity
between the lean and DIO mice in response to an acute dietary fat challenge, we
identified proteins associated with isolated CLDs by LC MS/MS. A protein was
considered identified in a treatment group if it was identified in at least 3 out of 5
biological replicates in at least one of the treatment groups. We identified a total of 375
proteins (Data not shown). Of the 375 identified proteins, a portion was found unique to a
treatment group, some found at similar levels and others were found at differentiated
levels (Figure 3).
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3.4.4

Proteins identified associated with CLDs from lean and DIO mice are associated
with a variety of biological processes

The gene ontologies associated with the 375 identified proteins were compared to
the complete mouse proteome and visualized using GOrilla (Data not shown). GOrilla
highlights biological processes which are enriched within the CLD associated protein
dataset. Biological processes highlighted in red indicate the most significant enrichment.
The proteins identified in the current analysis are associated with a wide variety of
biological processes (Data not shown). Biological process pathways that have the greatest
enrichment include oxidation-reduction process (GO:0055114), cellular lipid catabolic
process (GO:0044242), and organonitrogen compound metabolic process (GO:1901564).
To identify proteins which may contribute to CLD size and lipid accumulation, we
limited our analysis to the 81 (out of 375) proteins that are associated with lipid related
processes as determined using GOrilla (Data not shown).

3.4.5

Proteins associated with lipid related processes are found at differentially present
levels and have been previously characterized associated with CLD in enterocytes
proteomic or targeted protein analysis

Of the 81 lipid related proteins identified in the analysis, 25 are found either
unique or at differentiated present levels in lean and DIO samples (Table 1)Targeted
STRING analysis of lipid related proteins identify interacting protein clusters associated
with various lipid pathways.
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To identify lipid functional pathways enriched in the CLD proteome, we
conducted a STRING analysis of the 81 lipid related proteins (Figure 4). The STRING
analysis identified protein clusters related to lipoprotein metabolism, TAG storage and
mobilization, and fatty acid catabolism.The 25 proteins which are found unique or at
higher levels in either lean or DIO samples are indicated by green and red boxes
respectively and their relative levels are found in Table 1. Proteins found at higher levels
in DIO samples are associated mainly with fatty acid catabolism, lipid synthesis, and
lipid catabolism.

3.4.6

Plin3 and Plin2 localize to CLDs from lean and DIO mice in response to an acute
dietary fat challenge.

To confirm the presence of CLD associated proteins identified by CLD proteomic
analysis, we used immunofluorescence microscopy of 2 proteins which were identified,
Plin2 and Plin3 (Figure 5). Plin3 (A-B and E-F) is found at relatively equal abundance
associated with CLDs from lean (A-B) and DIO (E-F) mice. Plin2 (C-D and G-H) is
found at higher levels and forming a more distinct ring like structure around CLDs from
DIO mice (G-H) compared to lean mice (C-D). These results validate that Plin2 and 3
associate with CLDs in lean and DIO mice and Plin2 is present at differentiated levels.
An interesting observation was made regarding to the localization of Plin2 and Plin3,
particularly in DIO samples.
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Plin2 and Plin3 localize to different CLDs in different regions of the cell in DIO
mice.

Plin3 (A, C, and E) localizes to CLDs primarily in the apical region (above the
nucleus) of the cell. Plin2 (B, D, and F) localizes to CLDs both in the apical and
basolateral side of the cell.

3.5

Discussion

We investigated the effects of DIO on enterocyte CLD morphology and
associated proteins in response to an acute dietary fat challenge. DIO mice have larger
CLDs with a greater maximal size compared to lean (Figures 1 and 2). 375 proteins were
identified on CLDs from lean and DIO mice in response to an acute dietary fat challenge
(Data not shown). A portion of the proteins were found unique to one of the treatment
groups, a portion found at similar levels between the treatment groups, and some found at
differentially expressed levels (Figure 3). The identified proteins represent a diverse
range of proteins functions (Data not shown). Eighty one of the identified proteins are
associated with lipid related pathways (Figure 4). Of the 81 lipid related proteins, 25
proteins are either unique to CLDs from DIO mice or found at differentially present
levels in lean and DIO mice in response to an acute dietary fat challenge based on label
free quantitation levels (Table 1). Plin3 is found associated with CLDs from lean and
DIO mice at similar levels while Plin2 is found at increased levels on CLDs from DIO
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mice compared to lean in response to an acute dietary fat challenge (Figure 5). Plin2 and
Plin3 are found on different pools of CLDs in DIO mice in response to an acute dietary
fat challenge (Figure 6).
DIO alters CLD size which may contribute to the observed decreased TAG
secretion rates in DIO compared to lean mice in response to an acute dietary fat challenge.
High fat diet fed (non obese), ob/ob mice, and DIO mice have decreased TAG secretion
rates after an olive oil bolus, when lipoprotein lipase has been inhibited with tyloxapol [9,
10]. Interestingly, while there is a decrease in TAG secretion, analysis of intestinal
mucosa by either biochemical analysis or Coherent Anti-Scatter Ramen Spectroscopy[10]
demonstrated no difference in TAG content between lean and DIO in response to an
acute dietary fat challenge. The current study demonstrates an increased CLD size in DIO
and lean mice in response to an acute dietary fat challenge by transmission electron
microscopy. The difference between the current study and previous analysis of intestinal
mucosa is the use of transmission electron microscopy to identify the subcellular
localization of TAG in CLDs as compared to the analysis of the total enterocyte TAG
content. Biochemical and CARS analysis cannot distinguish between subcellular
localization of TAG in secretory or storage pathways in enterocytes. We hypothesize that
the decreased TAG secretion rate and increased TAG storage in CLDs in DIO mice
compared to lean in response to an acute dietary fat challenge may be an adaptation of
DIO mice to chronic consumption of a high fat diet. Adaptation of enterocytes to chronic
high fat diet feeding may allow the intestine to maintain efficient dietary fat uptake and
absorption.
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DIO alters CLD associated proteins in response to an acute dietary fat challenge.
Previous observations identified Plin3 localized to the CLD of lean mice in response to
an acute dietary fat challenge while Plin2 localized to the CLD of DIO mice under
chronic high fat feeding [13]. This study is the first report of CLD associated proteins in
enterocytes in DIO mice in response to an acute dietary fat challenge. Surprisingly, we
identified Plin2 on CLDs from lean mice in response to an acute dietary fat challenge. In
our previous report, we did not identify Plin2 associated with CLDs in enterocytes of lean
mice in response to an acute dietary fat challenge [13]. The previous results are consistent
with a lipid maturation hypothesis where Plin2 is thought of associating with more
mature CLDs and Plin3 associates with nascent CLDs [22]. While it is unclear why Plin2
was identified on CLDs from lean mice in response to an acute dietary fat challenge,
there are differences in the methodology in the current study compared to previous data
generated in our laboratory. The current study uses a more sensitive proteomic technique
to identify CLD associated proteins. Additionally, fresh frozen tissue used in the current
study allows for imaging of a greater number of enterocytes compared to isolated
enterocytes used in the previous report [13]. As seen in Figure 5, the Plin2 antibody
generates a weaker signal around the CLDs in lean mice compared to DIO mice in
response to a dietary fat challenge. It is possible that Plin2 was undetected in previous
reports because it was present at levels that were below the level of detection.
Lipid related proteins which were found identified either unique or at higher
abundance associated with CLD from DIO mice compared to lean in response to an acute
dietary fat challenge are similar to those found in models of hepatic steatosis induced by
high fat feeding. To further our understanding of the effect of DIO on CLD associated
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proteins we compared the findings of the current study to a previous report of liver CLD
associated protein induced by high fat feeding [12]. The liver is an appropriate model
system to compare the small intestine to in regards to lipid metabolism because they
share several common features such as the ability to generate both CLDs and lipoproteins.
Although both liver and intestine are capable of generating both triglyceride rich particles,
the liver is often thought as a storage site for TAG while the small intestine is thought of
as a through fare for TAG. A model of diet induced hepatic steatosis was used for
comparison. Hepatic steatosis was induced by chronic high fat feeding (60 kcal% BioServ, F3282 for 9 weeks) [12]. Several lipid related proteins which were found identified
either unique or at higher abundance associated with CLD from DIO mice compared to
lean in response to an acute dietary fat challenge which have also been previously
reported in the models of hepatic steatosis include ApoC2, Faah, Abcd3, and Acadvl [12].
It is unclear if these proteins are present due to the effect of obesity on a CLD
accumulation in response to an acute dietary fat challenge or if they are residual proteins
present on CLDs induced by high fat feeding from the previous meal of high fat diet. The
concept of proteomic differences between “old” CLD which are residual from the chronic
consumption of high fat diet and newly formed CLDs generated in response to a meal is
an interesting one, but this study does not address this issue.
Different CLD pools have different protein composition in response to an acute
dietary fat challenge. An unexpected observation made in this study was that Plin2 and
Plin3 localize to different CLD pools in enterocytes of DIO mice in response to an acute
dietary fat challenge (Figure 6). There are several lines of evidence suggesting that there
are sub populations of CLDs in various cell types with different proteins associated with
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them. While it has not been previously observed in the intestine, the perilipin family
members associate with CLDs at different times during CLD maturation in adipocytes
[22]. Additionally, members of the Cell death-inducing DNA fragmentation factor--like
effector (CIDE) family of proteins localize to different CLD subpopulations in
hepatocytes[23]. Lastly, TAG synthesis enzymes localize to different CLD sub
populations [24]. In particular AGPAT3 and GPAT4 colocalize on a subpopulation of
CLDs. More recently, it has been hypothesized that two groups of lipid droplets exist in
the cell. These CLDs are described as initial lipid droplets and expanding lipid droplets
which have their own distinct protein compositions[25]. The current study provides
supporting evidence for the possibility of different CLD subpopulations which have
distinct sub-proteomes and unique metabolism. This study highlights the power of
tandem mass spectroscopy to identify novel CLD associated proteins and compare the
CLD proteome under different conditions, however it cannot distinguish between
subpopulations of CLDs. This limitations highlights the need for microscopy techniques
to confirm the presence of proteins on or around CLDs and if it the protein localizes to
distinct CLD sub population.
Proteins that associate with CLDs in lean and DIO mice in response to an acute
dietary fat challenge are associated with a wide range of lipid related pathways (Figure 4
and Table 1). Proteins associated with lipid anabolic and catabolic pathways localize to
CLDs. TAG synthesis enzymes localize to CLDs in Cos7 cells[24] including GPAT4,
AGPAT3, ACSL1 and 3, and DGAT2. In the current study we identify Mogat2, Acsl5,
and Dgat1 associated with CLDs from DIO mice (Table 1). Although we did not measure
localized TAG synthesis, the presence of these TAG synthesis proteins on the CLD in
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response to an acute dietary fat challenge indicates the potential for localized TAG
synthesis. Enzymes that regulate CLD lipolysis have been well characterized in other cell
types including hepatocytes [26] and adipocytes [27] but enzymes that conduct lipolysis
in the intestine are under investigated. Several proteins which have been identified as
lipases in other cell types have also been identified in this analysis. Lipe (Hormone
sensitive lipase) was identified in CLDs from lean and DIO mice in response to an acute
dietary fat challenge. Members of the carboxylesterase family have been identified on
CLDs from lean and DIO mice. Some Carboxylesterase family members have been
characterized as lipases, however the isoform Ces1f, which was identified on the CLD
from DIO mice has not been characterized [28](Table 1), Arylacetamide deacetylase
(Aadac) was identified on CLDs from lean and DIO mice but at higher levels on CLDs
from DIO mice and has been characterized as a lipase in the HuH7.5 cells[29].
Additionally, members of the short-chain dehydrogenase/reductase family associate with
CLD and may regulate TAG storage. Members of the short-chain
dehydrogenase/reductase family including Dhrs1, HSD17B11, and HSD17B13 have been
identified on the CLD from lean and DIO mice. The role of these proteins on the CLD is
currently unknown, but evidence suggests that at least 1 family member, HSD17B13 is
associated with human subjects with NAFLD and over expression results in increased
accumulation of CLDs in mice[30].
The results from this study help generate a hypothetical model to generate
hypotheses for further investigation (Figure 7) to explain the effect of DIO on intestinal
lipid metabolism. DIO alters CLD morphology and associated proteins in response to an
acute dietary fat challenge. Proteins found associated with the CLD are associated with
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both anabolic and catabolic pathways. Proteins found associated with the CLD may
regulate the balance between storage of dietary TAG and the mobilization of TAG to be
utilized for chylomicron synthesis. The identification of proteins associated with TAG
lipolysis and lipid synthesis associated with CLDs from DIO mice may indicate that
mobilized FFA are being utilized for lipid synthesis directly on the CLD instead of being
utilized for chylomicron synthesis. This is consistent with the previously reported
decrease in TAG secretion observed in DIO mice in response to an acute dietary fat
challenge. The identified CLD associated proteins provide potential targets for further
investigation into the role of these proteins in dietary fat absorption
We demonstrated that DIO alters CLD morphology and associated proteins in
response to an acute dietary fat challenge. CLDs from DIO mice are larger with a
different size distribution compared to lean mice. CLDs from DIO mice have some
proteins in common and some unique compared to lean mice. Proteins found at higher
levels or unique to CLDs from DIO mice are associated with lipid catabolic and anabolic
pathways. Proteins identified in this analysis help expand upon the model of the effect of
DIO on dietary fat absorption.
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Table 3-1 Label free quantitation of proteins associated with lipid related Gene Ontology
terms.
375 identified proteins, 81 proteins are associated with lipid related Gene Ontology terms
as identified by GOrilla (Data not shown). Of the 81 lipid related proteins, 25 were found
at differentially present levels associated with CLDs from lean or DIO mice.

Majority
protein
IDs
Q3V2F7
Q9DBZ6
P37040

P51174

P50544

Q61425
Q3UUF0
Q91WU0
Q99PG0

Q922Z5
Q9QZQ8
Q3UKA4
Q8C3C9

Q91Y74

Q8N7N8

Protein names
Fatty acid-binding
protein, liver
ATP-binding cassette
sub-family D member 3
NADPH--cytochrome
P450 reductase
Long-chain specific
acyl-CoA
dehydrogenase,
mitochondrial
Very long-chain
specific acyl-CoA
dehydrogenase,
mitochondrial
Hydroxyacyl-coenzyme
A dehydrogenase,
mitochondrial
Fatty-acid amide
hydrolase 1
Carboxylesterase 1f
Arylacetamide
deacetylase
1-acylglycerol-3phosphate Oacyltransferase ABHD5
Core histone macroH2A.1
Alcohol dehydrogenase
1
Fatty aldehyde
dehydrogenase
CMP-Nacetylneuraminate-betagalactosamide-alpha2,3-sialyltransferase 4
HydroxymethylglutarylCoA synthase,
mitochondrial

Gene
names

Lean
LFQ
levels

DIO
LFQ
level
s

T
test
P
value

Intestinal
CLD

Pathway

Fabp1

23.72

25.10

0.029

[7]

Lipid binding

[5]

Lipid transport, fatty
acid oxidation
Oxidoreductase activity,
FAO

Abcd3
Por

22.20
21.99

23.92

0.017

Acadl

21.52

Mitochondrial beta
oxidation

Acadvl

22.56

Mitochondrial beta
oxidation

Hadh

22.80

Faah

20.65

Fatty acid catabolism

Ces1f

22.64

Triglyceride lipase

Aadac

21.66

23.41

Abhd5

21.53

H2afy

21.56

Adh1

20.21

[7]

0.011

Aldh3a2

22.16

23.47

0.049

St3gal4

23.34

24.37

0.013

Hmgcs2

21.33

Mitochondrial beta
oxidation

Triglyceride lipase

[5, 6]

Lipid homeostasis
Regulation of lipid
metabolism

[7]

Lipid metabolic process
Long-chain-aldehyde
dehydrogenase activity

[7]

Ganglioside metabolism
Cholesterol/steroid
biosynthesis
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G5E850

Q9EQ06
P49586

Cytochrome b5
Estradiol 17-betadehydrogenase 11
Choline-phosphate
cytidylyltransferase A

Cyb5

25.41

24.44

0.039

[7]

Sterol biosynthesis

Hsd17b11

23.46

25.38

0.027

[5, 6, 7]

Steroid synthesis

Pcyt1a

22.63

21.52

0.021

[5]

Phospholipid synthesis

Q8VC30

2-acylglycerol Oacyltransferase 2
Triosephosphate
isomerase
Bifunctional ATPdependent
dihydroxyacetone
kinase/FAD-AMP lyase

E0CXN5

Glycerol-3-phosphate
dehydrogenase
[NAD(+)], cytoplasmic

Gpd1

21.01

Q8VCR2

17-beta-hydroxysteroid
dehydrogenase 13

Hsd17b13

21.88

Q3UJG0

Apolipoprotein C-II

Apoc2

19.12

Q80W94
H7BXC3

Q3U711

Perilipin-2

Mogat2

19.78

[4]

Triglyceride synthesis

Tpi1

22.10

[5, 7]

G3P metabolic process

[7]

G3P metabolic process

[7]

G3P metabolic process

Dak

Plin2

22.79

23.92

21.85

25.99

0.005

Oxidation-reduction
process
Lipoprotein metabolism
0.026

[4, 5, 6,
13]

Lipid storage
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CHAPTER 4. LONG CHAIN FATTY ACYL COA SYNTHETASE 5 ABLATION
DECREASES TRIGLYCERIDE STORAGE IN ENTEROCYTES AND
SECRETION IN RESPONSE TO AN ACUTE DIETARY FAT CHALLENGE
COMPARED TO WILD TYPE MICE

4.1

Abstract

Acyl-CoA synthetases (ACSs) activate fatty acids generating fatty acyl-CoA
which is further metabolized by the cell. One member of the ACS family, long chain fatty
acyl Co-A synthetase 5 (Acsl5), is highly expressed in the intestine. Little is known of the
role of Acsl5 in the metabolism of dietary fat in enterocytes. To understand the role of
Acsl5 in dietary fat absorption, we challenged WT and Acsl5-deficient mice with acute
and chronic dietary fat challenges. Despite no evidence of quantitative fat malabsorption
in the absence of Acls5, we found significantly reduced TAG storage and secretion by
enterocytes compared to WT mice. Interestingly, Acsl5-deficient consumed more food,
but did not gain more weight compared to WT mice during two weeks of HFD feeding.
Furthermore, we found that Acsl5 localizes to the nucleus after an acute dietary fat
challenge. Together this data suggests that although Acsl5 is not essential for quantitative
dietary fat absorption, it plays a role in intestinal metabolism of dietary fat.
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4.2

Introduction

ACSs initiate the first step of fatty acid metabolism in the cell by converting fatty
acid to fatty acyl-CoA [1].There are 25 known members of the ACS family with different
tissue distribution patterns and fatty acid substrate preferences. Long chain fatty acyl
CoA synthetases (Acsls) prefer long chain fatty acids with chain lengths of 13-21 carbons.
Acsl5 is highly expressed in the small intestine, liver, and brown adipose tissue [2]. Acsl5
has multiple subcellular localizations including mitochondria [3-6] and ER [2, 5]. More
recently, Acsl5 was also identified [7, 8] and confirmed [8] to be associated with CLDs in
enterocytes. Multiple areas of sub cellular localization of Acsl5 suggest Acsl5 may play
multiple roles in cellular lipid metabolism.
ACSs can have multiple functions in cells including fatty acid uptake and
partitioning of fatty acids into different metabolic fates [9]. Over-expression of Acsl5 in
McArdle-RH7777 cells, a rat hepatoma cell line, increased fatty acid uptake, and
preferentially directed exogenous fatty acids toward TAG synthesis [3]. In a separate
study, knocking down Acsl5 by siRNA in rat primary hepatocytes decreased fatty acid
channeling toward anabolic pathways [10]. In this model, knocking down Acsl5
decreased incorporation of fatty acids into TAG, phospholipids, and cholesterol esters,
but did not affect fatty acid uptake. The decrease in incorporation of fatty acids into
complex lipids was accompanied by decreased CLD formation and lipoprotein secretion.
Lastly, Acsl5 knockdown cells have increased fatty acid oxidation. These results suggest
Acsl5 directs fatty acids toward anabolic pathways.
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To investigate the role of intestinal Acsl5 in dietary fat absorption, Meller et al.
generated an Acsl5-deficient mouse model[11]. Acsl5-deficient mice had a 60% decrease
in total ACS activity in the jejunum compared to WT mice. Despite the decrease in
ACSL activity, Acsl5-deficient mice had similar TAG secretion in response to an acute
dietary fat challenge compared to WT mice. Additionally, Acsl5-deficient mice had
similar growth curves when fed a Western Diet (17% protein, 49% carbohydrates, 21%
fat) compared to WT mice. This data suggests that Acsl5 does not play a role in dietary
fat absorption by the small intestine.
A new Acsl5-deficient mouse model has been generated with an improved
metabolic phenotype compared to WT mice. Whole body deletion of Acsl5 resulted in a
reduction of total Acsl activity by 80% in jejunal mucosa, 50% in liver, and 37% in
brown adipose tissue lysates [12]. Overall Acsl5-deficient mice had decreased fat mass,
increased metabolic rate, increased respiratory quotient, reduced serum TAG, and
improved insulin sensitivity. This is the mouse model that was used for this study.
To determine the role of Acsl5 in dietary fat absorption we challenged Acsl5=deficient
and WT mice with acute and chronic dietary fat challenges. We hypothesized that Acsl5
directs fatty acids toward TAG synthesis and that the absence of Acsl5 would result in a
decrease in enterocyte TAG storage in CLDs and a decreased secretion rate in response to
an acute dietary fat challenge. To test this hypothesis we analyzed TAG storage in the
jejunum section of Acsl5-deficient mice compared to WT mice in response to an acute
dietary fat challenge. Additionally, we measured TAG secretion in response to an acute
dietary fat challenge in Acsl5-deficient and WT mice. Lastly, to determine if Acsl5
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deficiency results in fat malabsorption as indicated by steatorrhea, we fed Acsl5-deficient
and WT mice a high fat diet and measured fecal lipid content.

4.3

Materials and methods

4.3.1

Diets and mice

All procedures were approved by the Purdue Animal Care and Use Committee. A
conditional, Acsl5-deficient mouse line was generated by Dr Andrew Greenberg at Tuft’s
University and backcrossed to C57Bl6J line as previously reported (Bowman 2016). All
mice were maintained on a 12- hour light/dark cycle (6AM/6PM) with ad libitum access
to food and water unless indicated. Mice were fed a chow diet or where indicated, a high
fat diet. This chow diet (PicoLab 5043, Lab Diets, Richmond, IN) has 62.1% of calories
from carbohydrate (starch), 24.7 % from protein, and13.2% from fat. The high fat diet
(D12492, Research Diets Inc, New Brunswick, NJ) has 20% calories from carbohydrate
(35% sucrose, 65% from starch), 20% from protein, and 60% from fat (lard). Mice were
euthanized via CO2 asphyxiation.

4.3.2

Tissue imaging

Mice were fasted for 4 hours at the beginning of the light cycle. Mice were then


olive oil bolus via oral gavage. Mice were euthanized 2 hours after

the oil bolus by CO2 asphyxiation. The small intestine was isolated and flushed with ice
cold PBS and divided into 5 equal sections. Sections 2 and 3, representing the jejunum,
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were analyzed. A small 1 cm2 section of the intestine was taken and cut longitudinally
exposing the lumen. The section was embedded in optimal cutting temperature media
(OCT) and frozen in 2-Methylbutane cooled by dry ice. Embedded tissue was stored at 20 C until sectioned.

         

   

   

plus charged microscopy slides (Fisher scientific, Hanover Park, IL, USA). The tissue
was fixed in 2% paraformaldehyde, and permeabilized with 0.1% saponin. The tissue was
probed with a previously validated antibody Acsl5 (a gift from Dr. Andrew Greenberg
from Tufts University, Boston MA, USA). The sections were also stained for neutral

    -difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene
(BODIPY) (Life technologies, Grand Island NY, USA), a secondary AlexaFluor antibody
(Life technologies), and for nuclei using 300 nM DAPI (Life technologies). The sections
were imaged using a Nikon A1R confocal microscope (Nikon Instruments Inc., Melville
NY, USA). Image processing was conducted using NIS- Elements C acquisition and
analysis software.
4.3.3

TAG secretion

To assess TAG secretion in response to an acute dietary fat challenge, mice were
fasted for 4 h, starting at the beginning of the light cycle. Mice were then injected with
tyloxapol (500 mg/kg) IP to block lipases required for clearance of TAG from blood.
Thirty minutes after tyloxapol injection, blood was collected via submandibular bleed for
analysis of plasma TAG concentrations (Time 0). Mice were then immediately gavaged
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gavage for plasma TAG analysis. Plasma TAG concentrations were determined by Wako
L-Type TG M kit (Wako Chemicals USA).

4.3.4

High fat feeding and food intake analysis

Mice were fed a high fat diet (60% kcal) for 2 weeks and body weights
determined weekly. To determine food intake, mice were housed individually in
metabolic cages and food was weighed daily for the last 4 days of high fat feeding.

4.3.5

Fecal lipid analysis

To assess fecal lipid content, feces were collected from mice for the last 4 days of
the 2 week high fat diet feeding. Feces were dried, weighed, ground using mortar and
pestle, and 0.5g was used for lipid analysis. Lipids were extracted using the Folch
extraction (2:1 chloroform: methanol) procedure. Percent fecal lipid content was
determined: (mg extracted lipid/mg dried feces)*100.
4.4

4.4.1

Results

Acsl5-deficient mice accumulate less neutral lipids in CLDs in response to an
acute dietary fat challenge compared to WT mice.

To assess the effect of Acsl5 on enterocyte neutral lipid storage in response to an
  







            

  -

deficient mice. Two hours after the acute dietary fat challenge, the small intestine was
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isolated, sectioned and stained for Acsl5, neutral lipids, and nuclei (Figure 1). Acsl5 is
present in enterocytes of WT mice (Fig 1A) but absent in Acsl5-deficient mice (Fig 1D).
WT mice had greater accumulation of neutral lipids (orange) (Fig 1B) compared to
Acsl5-deficient mice (E) in response to an acute dietary fat challenge.

4.4.2

Decreased TAG secretion in Acsl5-deficient mice compared to WT mice.

    

            olive oil bolus was

administered to WT and Acsl5-deficient mice pretreated with a lipase inhibitor, that
prevents clearance of TAG from blood, Tyloxapol. Blood was collected at T=0, 2, and 4
hours after the olive oil bolus. TAG secretion at 4 hours after an acute dietary fat
challenge was significantly reduced in Acsl5-deficient compared to WT mice (Fig 2).

4.4.3

Acsl5-deficeint mice have increased food intake without differences in body
weight or fecal lipid content compared to WT mice when fed a high fat diet.

To assess the effect of Acsl5 deficiency on weight gain, food intake, and
quantitative dietary fat absorption, WT and Acsl5-deficient mice were fed a HFD (60%
kcal) for two weeks body weight, food intake, and fecal lipid content were determined.
WT and Acsl5 had similar body weight curves during this time period (Fig 3a). Despite
similar body weight gain, Acsl5 deficient mice consumed significantly greater amounts
of food compared to WT mice during the last 3 days of HFD feeding (Fig 3b) with
similar excretion of lipid in feces (Fig 3c).
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4.4.4

Nuclear localization of Acsl5 in enterocytes in response to an acute dietary fat
challenge in WT mice.

To assess Acsl5 subcellular location in enterocytes in response to an acute dietary
  





l

bolus was administered to WT mice by oral gavage.

Samples from the jejunum section of the small intestine were isolated before the oil bolus
(after a 4 hour fast) and two hours after the oil bolus. The small intestine was isolated,
sectioned, and probed for Acsl5 (green) and counter stained for lipid (Bodipy, orange)
and nuclei (DAPI, blue) (Figure 4). Before the oil bolus, Acsl5 is found dispersed in the
cell (Figure 4A,B). Two hours after the oil bolus, Acsl5 distinctly localizes to nuclei
(Figure 4C-F).

4.5

Discussion

To understand the role of Acsl5 in dietary fat absorption, we challenged WT and
Acsl5-deficient mice with acute and chronic dietary fat challenges. Despite no evidence
of quantitative fat malabsorption in the absence of Acls5, we found significantly reduced
TAG storage and secretion by enterocytes compared to WT mice. Interestingly, Acsl5deficient consumed more food, but did not gain more weight compared to WT mice
during two weeks of HFD feeding. Furthermore, we found that Acsl5 localizes to the
nucleus after an acute dietary fat challenge. Together this data suggests that although
Acsl5 is not essential for quantitative dietary fat absorption, it plays a role in intestinal
metabolism of dietary fat.

133
Members of the ACSL family have been identified associated with CLDs and
contribute to CLD metabolism [13]. Recent proteomic analyses of isolated CLDs from
enterocytes identified [7, 8] and confirmed [8] Acsl5 localization to CLDs after a lipid
challenge. We found less TAG storage in CLDs in Acsl5-deficient mice in response to an
acute dietary fat challenge compared to WT mice. These results are similar to those
observed in primary rat hepatocytes where Acsl5 knockdown resulted in a decrease in
TAG storage [10]. Taken together, these results suggest that Acsl5 works in concert with
TAG synthesis machinery on the CLD to generate TAG for storage.
Blood TAG levels in the postprandial state are a balance between TAG secretion
from the intestine and clearance by peripheral tissues. We found that Acsl5-deficient
mice have reduced TAG secretion in response to an acute dietary fat challenge compared
to WT mice. These results are in contrast to previous reports from a different mouse
model that is also deficient in Acsl5 where TAG secretion rates were found to be similar
to WT mice [11]. There are several important differences between the two studies. The
differing genetic backgrounds might explain some of the observed phenotypic differences.
The Bowman Acsl5-deficient mice were on a pure C57BL6J background while the
Meller Acsl5-deficient mice were on a mixed C57BL6J/129sJ background. The Bowman
Acsl5-deficient mice had reduced total ACSL activity in liver extracts consistent with
previous published studies showing that siRNA knockdown of ACSL5 in isolated
hepatocytes significantly reduced total ACSL activity [10]. Meller et al. did not report the
expression of all of the other ACSL isoforms in their mouse livers, thus, another ACSL
isoform may have compensated for any reductions in ACSL activity. The two studies also
differ in experimental methodology. The first issue regarding the TAG secretion assay is
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the amount of dietary fat which was used to challenge the mice. The Meller mouse model

 



            live oil used in the

         

           

        !           "     
stress the intestine to delineate differences between Acsl5 deficient and WT mice. The
second issue regarding the TAG secretion assay is the time period of assessment. The
Meller mouse model collected blood samples until 90 minutes. In the current study, we
collected samples 4 hours after the dietary fat challenge and it was only at the 4 hour time
point that TAG secretion differs between Acsl5 deficient and WT mice. These data
suggests that Acsl5 regulates dietary fat secretion in the small intestine, however under
specific physiological conditions.
Deficiencies in dietary fat uptake and secretion are often accompanied by fat
malabsorption. Since Acsl5 deficient mice have a decrease in TAG storage and TAG
secretion compared to WT mice, we analyzed fecal lipid content in mice fed a high fat
diet to assess steatorrhea. Surprisingly, Acsl5 deficient mice do not have an increase in
fecal lipid content compared to WT mice when fed a high fat diet. One hypothesis to
explain this observation is Acsl5 deficient mice take up fatty acids in different regions of
the small intestine compared to WT mice. Acsl5 deficient mice may have lower rates of
fatty acid uptake in enterocytes in the upper region of the intestine; instead take up
dietary fatty acids in smaller quantities in different regions. By diffusing dietary fat
uptake along the length of the intestine, Acsl5 deficient mice can have decreased TAG
secretion rates and TAG storage without fat malabsorption. In this study we only assessed
TAG storage in the jejunum section of the small intestine and only assessed TAG
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secretion and uptake on a whole body physiological level. Future studies to assess fatty
acid uptake and TAG storage and secretion at a cellular level in specific regions of the
small intestine are important to clarify this issue.
We also investigated weight gain and food intake of high fat diet in Acsl5
deficient mice and WT mice. Acsl5-deficient and WT mice consumed similar quantities
of food when fed a chow diet [12]. When Acsl5-deficient mice were fed a HFD however,
Acsl5-deficient mice consumed significantly more food compared to WT mice. Increased
food intake may be attributed to a number of factors and the factors which influence an
increase in food intake on a HFD in Acsl5 deficient compared to WT mice have not been
studied. One hypothesis for increased food intake in Acsl5 deficient mice compared to
WT mice is an increased circulating level of FGF21[12]. Overexpression of FGF21
increases food intake when mice are fed chow or high fat diets [15]. Acsl5-deficient mice
may consume more high fat diet compared to WT mice due to their increased levels of
serum FGF21. Despite the increase in food intake, Acsl5 deficient mice had similar
weight gain on high fat diet compared to WT mice when fed for a 2 week period. The
increase in caloric intake may be offset by the increased energy expenditure in Acsl5deficient mice compared to WT mice [12].
A surprising observation made during imaging of Acsl5 in response to an acute
dietary fat challenge was the dramatic change in subcellular localization of Acsl5. In the
before an oil bolus, Acsl5 is found dispersed in the cell, however when WT mice are
given an acute dietary fat challenge, Acsl5 distinctly localizes to the nucleus of
enterocytes. Acsl5 is known to localize to mitochondria and CLDs in enterocytes [4, 8]
however nuclear localization pattern of Acsl5 has not been previously observed in
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enterocytes. The presence of long chain fatty acyl-CoA and ACSLs has been detected in
the nucleus of rat liver [16-20]. Acyl-CoAs are thought to be present within the nucleus
and serve as ligands for transcription factors that may regulate expression of proteins
involved in TAG storage and secretion. Acyl-CoAs may be transported into the nucleus
or based on this observation generated within the nucleus. This unexpected discovery
represents a very interesting area for future research.
Acsl5 plays a role in intestinal lipid metabolism in response to dietary fat. Despite
no evidence of quantitative fat malabsorption in the absence of Acls5, we found
significantly reduced TAG storage and secretion by enterocytes compared to WT mice.
Interestingly, Acsl5-deficient consumed more food, but did not gain more weight
compared to WT mice during two weeks of HFD feeding. Furthermore, we found that
Acsl5 localizes to the nucleus after an acute dietary fat challenge. Together this data
suggests that although Acsl5 is not essential for quantitative dietary fat absorption, it
plays a role in intestinal metabolism of dietary fat.
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Figure 4-2 Decreased TAG secretion in Acsl5-deficient mice compared to WT mice.
Postprandial TAG secretion rate was measured in WT and Acsl5 -/- mice. Mice were
injected with 500 mg/kg Tyloxapol into the interperitoneal cavity to inhibit lipoprotein
lipase activity. Thirty minutes after Tyloxapol injection, the mice were bled (T=0) and
     
                  
post oil bolus. Data represented as mean +/- SEM. Asterisk denotes significant difference
at the time point (Student T test, p<0.05). n= 3-5 male mice.
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Figure 4-3 Acsl5-deficeint mice have increased food intake without differences in body
weight or fecal lipid content compared to WT mice when fed a high fat diet
No different in body weight between Acsl5-/- and WT mice on a high fat diet for 2 weeks.
Body weights of Acsl5 -/- and WT mice fed a high fat diet (60% kcal) were monitored
for 2 weeks (A). No difference in body weight was determined using a Student t test
(p<.05) Data represented as mean +/- SEM. n= 4-5 mice. Increased food intake of Acsl5 /- mice compared to WT mice when fed a high fat diet (B).Food intake was monitored
during the last 4 days of a two week period of high fat diet (60% kcal) feeding. Acsl5 -/mice had increased food intake compared to WT mice as determined by a Student t test (*
p<.05). Data represented as mean +/- SEM n= 4-5 mice. No difference in fecal lipid
content in Acsl5 -/- compared to WT mice after 2 weeks of high fat feeding (C). Acsl5 -/and WT mice were fed a high fat diet (60% kcal) for 2 weeks. Fecal samples were
collected during the last 4 days of feeding. Lipid content was determined by Foch
extraction of ground feces. Data represented as mean +/- SEM. No difference in fecal
lipid content levels was determined by Student T Test p <.05 n=4-5 male mice.
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CHAPTER 5. SUMMARY AND FUTURE DIRECTIONS

5.1

Summary

Dietary fat provides essential nutrients, contributes to energy balance, and
regulates blood lipid concentrations. These functions are important to health, but can also
become dysregulated and contribute to diseases such as obesity, diabetes, cardiovascular
disease, and cancer. Within enterocytes, the digestive products of dietary fat are resynthesized into triacylglycerol, which is either secreted on chylomicrons or stored within
cytoplasmic lipid droplets (CLDs). CLDs were originally thought to be inert stores of
neutral lipids, but are now recognized as dynamic organelles that function in multiple
cellular processes in addition to lipid metabolism. The objective of this dissertation was
to investigate CLDs and associated proteins and their role in dietary fat absorption.
To identify regulators of CLD metabolism we analyzed the proteomic profile of
isolated CLDs from enterocytes in response to an acute dietary fat challenge. We
identified 181 proteins associated with the isolated CLD fraction using high resolution
tandem mass spectrometry. Interestingly, the identified proteins are associated with a
wide range of biological and molecular functions. Several of the identified proteins have
been previously identified in other CLDs proteomic analyses from many cell types, while
other identified proteins have not been previously reported. Furthermore, we confirmed
the localization of Plin3, ApoA-IV, and Acsl5 to CLDs by immunohistochemistry and
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immunoelectron microscopy. Additionally, we investigated the effect of DIO on
intestinal CLD morphology and associated proteins. We demonstrated that DIO mice
have larger CLDs compared to lean mice in response to an acute dietary fat challenge.
CLDs isolated from DIO mice have some proteins in common and some unique
compared to CLDs isolated from lean mice in response to an acute dietary fat challenge.
Proteins found at higher levels or unique to CLDs isolated from DIO mice are associated
with both lipid anabolic and catabolic pathways. The newly identified CLD associated
proteins expand upon the model of protein regulators of CLD metabolism in enterocytes.
Lastly, we investigated the role of Acsl5 in dietary fat absorption. To characterize
the role of Acsl5 in the small intestine we challenged Acsl5-deficient mice and WT mice
with acute and chronic dietary fat challenges. We demonstrate Acsl5-deficient mice have
decreased TAG secretion and decreased neutral lipid storage in response to an acute
dietary fat challenge. Additionally, we show Acsl5-deficeint mice have no defect in
quantitative dietary fat absorption when placed on a high fat diet for two weeks.
Additionally, Acsl5-deficient mice have increased food intake without associated weight
gain compared to WT mice when fed a high fat diet. Lastly, we observed a dramatic shift
to nuclear localization of Acsl5 in response to an acute dietary fat challenge. Taken
together, these results indicate that Acsl5 plays an important role in dietary fat
metabolism.
The results presented in this dissertation identify new regulators of CLD
metabolism and dietary fat absorption in the small intestine. These results provide the
groundwork for further investigation into mechanistic details of dietary fat absorption.
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5.2

Future directions

The chapters in this dissertation highlight how much is unknown regarding the
role of CLDs in dietary fat absorption. Several areas of unanswered questions include 1)
identifying differences in CLD morphology and associated proteins in different regions
of the intestine, 2) identifying changes in CLD morphology and associated proteins over
time, and 3) what role Acsl5 plays in the nucleus of enterocytes.

5.2.1

CLD morphology and associated proteins along the length of small intestine

Enterocytes along the length of the intestine are capable of absorbing dietary fat
however the mechanistic details of dietary fat absorption along the length of the intestine
is relatively unknown. When a small amount of dietary fat is administered, the majority is
taken up in the proximal section of the intestine. When dietary fat load increases, the
lower region of the small intestine absorbs dietary fat [1]. Most dietary TAG is taken up
and stored in CLDs in the proximal section of the small intestine, however TAG storage
occurs along the length of the intestine with smaller quantities found in the distal regions
[2]. Little is known about CLD morphology and associated proteins in the duodenum and
ileum. Regulators of CLD metabolism may differ in different regions of the intestine and
alter that region’s contribution to post prandial lipedema. Identifying CLD associated
proteins along the length of the intestine is important for identifying regulators of dietary
fat absorption, particularly when a large amount of dietary fat is consumed.
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5.2.2

Changes in CLD morphology and associated proteins over time in response to an
acute dietary fat challenge.

CLDs are dynamic stores of TAG which increase and decrease over time in
response to an acute dietary fat challenge [2]. This dynamic nature is most likely
regulated by proteins which associate with the CLD. CLD protein composition changes
over time in other cell types [3, 4]. We hypothesize CLDs associated proteins in
enterocytes change over time as CLDs grow and shrink. To test this hypothesis, we
would administer an acute dietary fat challenge to mice and isolate CLDs from
enterocytes at 1, 2, 4, and 6 hours after the bolus. Proteins associated with the CLDs at
these time points will be identified by high resolution tandem mass spectroscopy.
We would predict protein composition to change based on protein function and
protein structure. We would predict proteins identified at earlier time points would
include more lipid synthesis proteins compared to later time points. Lipid synthesis
enzymes would allow nascent CLDs to grow and store TAG and other neutral lipid
species. Conversely we would expect more lipid catabolism proteins to be present on
CLDs at later time points compared to earlier time points to mobilize stored lipid.
Additionally, we would predict protein composition to change over time based on
protein structure. Proteins identified at later time points may have structural features
which would allow the protein to directly bind to CLDs. Proteins loosely associated with
CLDs are predicted to be displaced as stored TAG is catabolized and the CLDs shrink [5].
Identifying how CLD associated proteins change over time can identify important
regulators of CLD metabolism and TAG secretion rate.
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5.2.3

The role of Acsl5 in the nucleus

Localization of Acsl5 to the nucleus of enterocytes in response to dietary fat
challenge may regulate dietary fat absorption in the small intestine. Long chain fatty acylCoA has been identified in the nucleus in other cell types. Isolated nuclei from rat livers
contain C16:1-CoA and C18:3-CoA [6, 7]. Additionally, long chain fatty acyl-CoA
synthestase activity has been detected in isolated rat liver nuclei for a variety of long
chain fatty acids [8, 9]. Lastly, long chain fatty acyl-CoAs act as ligands for hepatic
nuclear factor 4 alpha (Hnf4a) [10].
Hnf4a is expressed in the enterocyte and are activated by fatty acids derived from
the luminal side of the enterocytes [11]. Hnf4a controls the expression of lipid
metabolism genes including genes coding for apolipoproteins and microsomal
triglyceride transfer protein (Mttp). Mice with an intestine specific inducible Hnf4a
knockout have decreased triglyceride tolerance and decreased triglyceride secretion
compared to Hnf4a loxp/loxp counterpart [12]. Hnf4a knockout mice have decreased
Apolipoprotein B and Mttp protein expression, Mttp activity and decreased TAG
accumulation in enterocytes in the post oil bolus state [13]. The similarities between
Hnf4a knockout mice and Acsl5-deficient mice suggest the two proteins may share
similar biological pathways or are mechanistically connected.
We hypothesize that Acsl5 localizes to the nucleus in response to a dietary fat
absorption to provide long chain fatty acyl-CoA to serve as ligands for Hnf4a. The
nuclear localization of Acsl5 indirectly regulates intestinal dietary fat uptake, metabolism,
and secretion. To test this hypothesis we will confirm the localization and activity of
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Acsl5 in isolated nuclei from enterocytes. We will confirm the presence of Acsl5 in
isolated nuclei by Western Blotting analysis and acyl-coa synthetase activity using a
variety of long chain fatty acids in an activity assay. Additionally, we will look at
expression of Acsl5 downstream target genes in the post bolus state in WT and Acsl5deficeint mice. Finally, we will determine the binding of Hnf4a to downstream targets
using an electrophoretic mobility shift assay in WT and Acsl5-deficient mice. The results
of these experiments will indirectly demonstrate the regulation of Hnf4a by Acsl5.
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